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ABSTRACT 
Diabetes mellitus is defined as a group of metabolic disorders characterised by chronic 
hyperglycaemia due to insufficient production and/or action of insulin and is regarded as one 
of the major sources of morbidity, mortality and economic burden to the modern society. A 
large body of scientific evidence support the fact that oxidative stress is elevated in diabetic 
conditions. Oxidative stress plays a significant role in the development of secondary 
complications of diabetes including diabetes-linked male sexual dysfunction. The 
management of sexual dysfunction as a secondary complication of diabetes relies on the 
management of the underlying diabetic condition. Glycaemic control and increased 
antioxidant protection are therefore necessary in the management of diabetes-induced 
oxidative stress male infertility. 
 
Pharmacological management of diabetes in form of various antihyperglycaemic, synthetic 
drugs has improved the outlook of diabetic patients; however, they are expensive, harbour 
unfavourable adverse effects and some have done little to prevent secondary complications 
of diabetes including diabetes-induced male sexual dysfunction. In addition to this, access to 
basic technologies for the management of diabetes mellitus and its secondary complications 
is still a challenge in low resource areas. Because of these challenges, there is a need to 
search for alternative remedies such as medication from natural products which are more 
affordable, well tolerated by the human body and are easily accessible. Medicinal plants are 
therefore viewed as an easily accessible and potent source of antioxidants capable of 
scavenging free radicals and fighting diabetes-induced oxidative stress. This study therefore 
investigated the effects of vindoline; an alkaloid extractable from Cantharanthus roseus in 
ameliorating diabetes-induced oxidative stress effects in testicular and epididymal tissues 
using male Wistar rats. 
 
Forty-eight (48), 6-week old male Wistar rats weighing between 190-230g with a 
conventional microbial status were divided into 6 groups, n=8, and used for this research 
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project. Group 1 was the normal control, group 2 comprised non-diabetic rats treated with 
vindoline, and group 3 was the non-diabetic group of rats treated with glibenclamide- the 
standard drug for the treatment of diabetes. Group 4 was the diabetic control, group 5 
comprised diabetic rats treated with vindoline and group 6 was the diabetic group of rats 
treated with glibenclamide. Diabetes was induced in group 4, group 5 and group 6 rats by 
subjecting them to 10% fructose water over a period of 2 weeks and thereafter, administering 
a single intraperitoneal injection of 40 mg/kg b.w streptozotocin (STZ). Fasting blood glucose 
levels were measured 72 hours after STZ injection and hyperglycaemia was confirmed 
where fasting blood glucose levels were more than 18mmol/l.  
 
The diabetic control (group 4) had higher fasting blood glucose levels, lower body weights as 
well as lower testicular and epididymal weights in comparison to the normal control (group 1). 
Additionally, the extent of lipid peroxidation in testicular and epididymal tissues of the diabetic 
control (group 4) was higher in comparison to that of the normal control (group 1). The 
diabetic control had lower testicular and epididymal antioxidant enzyme activities (superoxide 
dismutase and catalase) and lower oxygen radical absorption capacity (ORAC) in 
comparison to the normal control. Ferric reducing antioxidant power (FRAP) in testicular and 
epididymal tissues of the diabetic control (group 4) were not significantly different from those 
of the normal control (group 1). 
 
Treatment of diabetic rats with vindoline (group 5) for 5 weeks significantly reduced fasting 
blood glucose levels although the extent of reduction could not restore diabetic blood glucose 
levels to near-normal levels. Overall, treatment of diabetic rats with vindoline was able to 
minimise testicular oxidative stress as reflected by reduction in testicular malondialdehyde 
(MDA) levels. Furthermore, results of this study showed an increase in both testicular and 
epididymal catalase activities, an increase in epididymal SOD, an increase in testicular 
ORAC as well as an increase in both testicular and epididymal FRAP levels after 5 weeks of 
treating diabetic rats with vindoline (group 5). Epididymal lipid peroxidation levels, epididymal 
ORAC levels and testicular SOD levels of diabetic rats treated with vindoline (group 5) were 
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however not significantly different from those of the diabetic control (group 4). Treatment of 
diabetic rats with vindoline or glibenclamide could not restore total body weights and 
testicular weights of group 5 and group 6 rats respectively, to near-normal levels. 
Furthermore, epididymal weights and testicular SOD activity of diabetic rats treated with 
vindoline (group 5) were not significantly different from those of the normal control (group 1). 
 
In conclusion, findings from this study demonstrated that treatment with vindoline could have 
protective effects against diabetes-induced oxidative stress in both testicular and epididymal 
tissues of male Wistar rats. Vindoline can therefore be considered a potential agent for the 
management of diabetes-induced oxidative stress male sexual dysfunction. Further studies 
with advanced technologies are however recommended to study the possible efficacy of 
vindoline in ameliorating diabetes-induced oxidative stress male sexual dysfunction. 
Furthermore, studies on the dose-dependent effects and long-term effects of vindoline 
administration on male reproductive function as well as the overall safety of treatment with 
vindoline are necessary. 
 
Keywords: Diabetes mellitus, Oxidative stress, Vindoline, Catharanthus roseus, Testicular 
tissue, Epididymal tissue. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background 
Diabetes mellitus is a potentially devastating, incurable yet treatable lifelong metabolic 
disorder whose prevalence is rapidly increasing (Al-Attar & Zari, 2010; Bommer et al., 2018). 
In the last few decades, the worldwide prevalence of diabetes has increased enormously due 
to a multitude of factors including general population growth, urbanisation, aging and an 
increase in obesity cases as a consequence of physical inactivity (Tiwari et al., 2013). In 
2014, the global prevalence of diabetes amongst adults aged 18 and above was 422 million, 
in comparison to 108 million in 1980. These results show that the global age-standardized 
(adults aged 18 and above) prevalence of diabetes rose from 4.7% to 8.5% between the 
years 1980 and 2014 (World Health Organisation, 2016).  
 
Diabetes has become one of the major sources of morbidity, mortality and economic burden 
to the modern day world (World Health Organisation, 2014; da Rocha et al., 2016; Ogurstova 
et al., 2017). In the year 2000, the prevalence of diabetes mellitus in the World Health 
Organization African region was estimated to be 7.02 million (World Health Organisation, 
2008). Amongst these, 113 100 people died as a result of diabetes-related causes, 561 600 
people suffered permanent disability while 6 458 400 experienced temporary disability as a 
consequence of diabetes mellitus (Kirigia et al., 2009). In 2015, the worldwide economic 
burden of diabetes was estimated to be USD1.31 trillion, a value that accounted for 
approximately 1.8% of the global gross domestic product with an estimated two thirds of 
these costs attributed to direct medical costs for the treatment of diabetes mellitus and the 
remaining third related to loss of productivity (Bommer et al., 2017). 
 
The incidence of diabetes has been shown to rise in association with the increasing 
incidence of infertility amongst men of reproductive age (Agbaje et al., 2007). Diabetes has 
been established as one of the risk factors for the development of male sexual dysfunction. 
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Multiple studies using both diabetic men and animal models demonstrate that diabetes 
mellitus has detrimental effects on male reproductive function (La-Vignera et al., 2012; 
Ukwenya et al., 2013; Ghosh et al., 2014; Giribabu et al., 2014; Jain & Jangir, 2014; Ding et 
al., 2015) . A large body of scientific evidence support the fact that oxidative stress is 
elevated in diabetic conditions as a consequence of the overproduction of reactive oxygen 
species (ROS) without adequate neutralization of these harmful chemical entities by the 
body`s antioxidant system (Rochette et al., 2014; Asmat et al., 2015; Chikezie et al., 2015). 
This oxidative stress plays a pivotal role in the development of diabetes secondary 
complications (Giacco & Brownlee, 2010). Multiple studies indicate that diabetes-induced 
oxidative stress has a negative impact on male reproductive capacity (Chatterjee et al., 2012; 
Suresh et al., 2013; Singh et al., 2013; Ukwenya et al., 2013, Giribabu et al., 2014; Hajizadeh 
et al., 2014; Shah & Khan, 2014; Maresch et al., 2018). Diabetes-induced oxidative stress 
can compromise spermatozoal quality, alter testicular morphology, alter spermatogenesis, 
reduce testosterone levels, reduce libido and promote retrograde ejaculation (La-Vignera et 
al., 2012; Jain & Jangir, 2014; Oliveira et al., 2015; Elabbady et al., 2016). Oxidative stress 
generated in diabetic conditions is also responsible for the oxidation of spermatozoal lipids, 
proteins and deoxyribonucleic acids (DNA). Peroxidative damage of spermatozoal 
membrane lipids impairs spermatozoal motility while DNA oxidation disrupts the 
spermatozoal genome (Bucak et al., 2010; Tvrdá et al., 2011). The oxidation of proteins on 
the other hand, results in site-specific amino acid modifications, altered electric charge and 
increased susceptibility of spermatozoa to proteolysis (Tvrdá et al., 2011). The collective 
effect of diabetes-induced oxidative stress may therefore precipitate infertility in male diabetic 
patients. 
 
The management of sexual dysfunction as a secondary complication of diabetes relies on 
the management of the underlying diabetic condition (Tremellen, 2008). The maintainence of 
blood glucose homeostasis and increase in antioxidant levels in diabetic patients are 
therefore important in the management of diabetes-induced oxidative stress male infertility 
(Singh et al., 2013; Chaudhury et al., 2017). Consumable and behavioural therapies capable 
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of countering the effects of diabetes-induced oxidative stress may be useful in reducing the 
extent of diabetic complications (Tiwari et al., 2013) including diabetes-linked male infertility. 
 
Lifestyle management is the major therapeutic option for diabetes and involves regular 
exercise and weight control measures amongst others (American Diabetes Association, 
2017). Besides lifestyle management, pharmacological management of diabetes in form of 
insulin therapy and the use of hypoglycaemic drugs have improved the outlook of diabetic 
patients; however, synthetic antidiabetic drugs are expensive, harbour unfavourable side 
effects and in some cases have done little to prevent the development of diabetes-related 
secondary complications (Siddiqui et al., 2013; Chaudhury et al., 2017). In addition to this, 
lack of access to insulin and basic technologies crucial for the management of diabetes 
remain a key impediment to the successful treatment of diabetes with oral hypoglycaemic 
agents and insulin being reported as generally available in only a minority of low income 
countries (World Health Organisation, 2016).  
 
Because of these challenges in the management of diabetes, the search for alternative 
remedies such as medications from natural products is paramount (Saxena & Kishore, 
2004). An antioxidant capable of reducing oxidative stress could be useful in the 
management of oxidative stress-induced male infertility (Bansal & Bilaspuri, 2011). Due to 
their hypoglycaemic and antioxidant potential, a variety of medicinal plants have been used 
in the management of diabetes mellitus (Singh et al., 2013). Medicinal plants are a rich 
source of bioactive constituents that can effectively lower blood glucose levels (Rizvi & 
Mishra, 2013). Some of their phytochemicals are viable antioxidants capable of ameliorating 
oxidative stress-induced diabetic complications such as testicular and epididymal oxidative 
stress as seen in diabetes (Oliveira et al., 2015). In view of this, the use of medicinal plants 
can be a source of new hope, as an affordable and easily accessible prevention and 
treatment method with fewer side effects.   
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Catharanthus roseus (L.) G. Don Linn (C. roseus) is an ornamental shrub commonly known 
as the Madagascar periwinkle, as it is native to Madagascar (Tiong et al., 2013). C. roseus 
extracts are a viable source of natural antioxidants and hence might be exploited for 
nutraceutical applications (Rasool et al., 2011; Patharajan & Abirami, 2014). Phytochemical 
analysis of C. roseus shows the presence of alkaloids, terpenoids, steroids, flavonoids as 
well as some other useful secondary metabolites (Aslam et al., 2010). Previous studies have 
demonstrated the antihyperglycaemic and antioxidant activities of various extracts from C. 
roseus (Rasineni et al., 2010; Vega-Vila et al., 2012; Al-Shaqha et al., 2015). Vindoline is an 
intermediate, semi-synthetic, vinca alkaloid, extractable from C. roseus that has been 
reported to exhibit antidiabetic properties in diabetes-induced animal models by increasing 
glucose-stimulated insulin release, lowering blood glucose levels, inhibiting Kv 2.1 potassium 
channels, decreasing the potassium ion outward current, lowering glycated haemoglobin, 
reducing triglyceride levels and inhibiting H+/K+ ATPases (Sertel et al., 2011; Tiong et al., 
2013; Yao et al., 2013). Despite the available few studies on the antidiabetic and antioxidant 
properties of vindoline, no specific research has reported on the effects of vindoline on 
reproductive functions of diabetic men or diabetes-induced animal models.  
 
1.2. Research Problem 
Oxidative stress is one of the predominant causes of diabetes secondary complications 
amongst which is male sexual dysfunction and infertility (Giacco & Brownlee, 2010). High 
blood glucose levels as seen in diabetic conditions promote the generation of ROS species 
and in the absence of an appropriate compensatory response from the antioxidant system, 
loss of equilibrium in favour of oxidizing species occurs and this phenomenon is known as 
oxidative stress (Asmat et al., 2015). The impairment of testicular and epididymal antioxidant 
response in diabetic men affects male fertilizing potentials (Mallick et al., 2007; Hamden et 
al., 2008). Glycaemic control and increased antioxidant protection are therefore crucial in the 
management of diabetes-induced male infertility (Singh et al., 2013). Although the use of 
hypoglycaemic agents has improved the outlook of diabetic patients, many of them harbour 
serious adverse effects, are expensive, require expertise (Modak et al., 2007) and in some 
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cases have done little to control secondary complications of diabetes including diabetes-
linked male infertility (Gurib-Fakim, 2006). As such, the management of diabetes without side 
effects remains a challenge and the search for alternative remedies such as medication from 
natural products is paramount (Saxena & Kishore 2004). Medicinal plants are regarded as 
easily accessible sources of antioxidants capable of scavenging free radicals and fighting 
diabetes-induced oxidative stress. Additionally, medicinal plants have proven to be clinically 
effective and relatively less toxic as compared to synthetic hypoglycaemic agents currently in 
use for the treatment of diabetes mellitus (Bhatt et al., 2013).  
 
1.3. Aim 
To investigate the possible therapeutic effects of vindoline on testicular and epididymal 
function, using diabetes-induced oxidative stress male Wistar rats as an experimental model. 
 
1.4. Objectives  
This study was designed to evaluate the effects of vindoline on testicular and epididymal 
function of both normal and diabetic male Wistar rats. The objectives of this study include the 
following: 
i. To determine if treatment with 10% fructose water for 2 weeks and a single STZ dose 
can induce diabetes mellitus associated with oxidative stress in adult male Wistar 
rats. 
ii. To investigate whether treatment with vindoline has an effect on the body, testicular 
and epididymal weights of diabetes-induced oxidative stress male Wistar rats. 
iii. To investigate the effects of vindoline on lipid peroxidation in testicular and 
epididymal tissues of diabetic and non-diabetic rats as expressed by 
malondialdehyde (MDA) biomarkers. 
iv. To assess the effect of vindoline on testicular and epididymal antioxidant enzyme 
activities such as superoxide dismutase and catalase, using diabetic and non-diabetic 
rats as experimental models. 
 6
v. To investigate if treatment with vindoline can reduce, modulate or inhibit the induced 
oxidative stress effects in testicular and epididymal tissues as represented by ORAC 
and FRAP assays. 
 
1.5. Research Questions 
i. Is treatment with 10% fructose water for 2 weeks and a single intra-peritoneal 
injection of STZ (40mg/kg b.w.) sufficient to destroy pancreatic β-cells thereby 
causing persistent hyperglycaemia?  
ii. What are the effects of vindoline on the body, testicular and epididymal weights of 
diabetes-induced male Wistar rats and non-diabetic controls? 
iii. What could be the potential impact of vindoline on lipid peroxidation, as expressed by 
MDA levels in testicular and epididymal tissues of diabetic and non-diabetic rats? 
iv. How would antioxidant enzymes such as superoxide dismutase and catalase differ 
between diabetic rats treated with vindoline and untreated groups? 
v. Does treatment with vindoline reduce, modulate or inhibit the induced oxidative stress 
effects in testicular and epididymal tissues as expressed by ORAC (Oxygen Radical 
Absorbance Capacity) and FRAP (Ferric Reducing Antioxidant Power) assay results? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7
CHAPTER 2 
LITERATURE REVIEW 
2.1. Diabetes 
The rapidly increasing incidence of diabetes is becoming a serious threat to human health in 
all parts of the world (Malviya et al., 2010). Diabetes is defined as a group of metabolic 
disorders characterized by chronic hyperglycaemia due to insufficient production or action of 
insulin (American Diabetes Association, 2009). In a healthy person, blood glucose levels are 
regulated by several hormones, primarily insulin which is produced by the pancreas. Insulin 
allows glucose to move out of the blood into the cells throughout the body where it is used for 
fuel. In diabetic conditions, the production of insulin is not enough or the target cells are 
resistant to the available insulin or both. As such, blood glucose cannot move into cells 
effectively and hence remain at high levels in the blood; a phenomenon known as 
hyperglycaemia. This not only starves cells of glucose for fuel, but also harms organs like the 
brain and other tissues by exposing them to high blood glucose levels (Siddiqui et al., 2013). 
 
2.2. Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) is characterized by processes of autoimmune mediated 
destruction of the β-cells of the pancreas (Tomita, 2017). Because patients with T1DM 
require insulin for survival, T1DM is alternatively known as insulin-dependent diabetes 
mellitus (Asmat et al., 2015). Markers of immune destruction e.g. insulin autoantibodies and 
antibodies to glutamic acid decarboxylase are present in patients with T1DM (Taplin & Baker, 
2008). T1DM causes a state of intracellular hypoglycaemia and extracellular hyperglycaemia 
(Asmat et al., 2015). Intracellular hypoglycaemia causes glycogenolysis whereby glycogen 
molecules are broken down to individual glucose molecules and gluconeogenesis whereby 
glucose is generated from non-carbohydrate sources such as amino acids, lactate and 
glycerol. When the body uses fat as an alternative source of energy, ketones accumulate in 
the blood making it acidic. This phenomenon is known as diabetic acidosis and it may lead to 
a coma and eventually death (Gillespies, 2006). On the other hand, extracellular 
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hyperglycaemia leads to a hyperglycaemic coma and osmotic diuresis (Ozougwu et al., 
2013). 
 
2.3. Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is the most common type of diabetes mellitus accounting 
for almost 90-95% of all diabetic cases (Rubino, 2008). T2DM is characterized by excessive 
hepatic glucose production, decreased insulin secretion as well as insulin resistance 
(Guillasseau et al., 2008). Unlike patients with T1DM, risk of ketoacidosis is infrequent and 
T2DM patients do not need insulin for survival. As such T2DM is alternatively known as non-
insulin-dependent diabetes mellitus (Asmat et al., 2015). There is convincing data to indicate 
genetic components associated with T2DM insulin resistance (Ali, 2013; Corbi et al., 2017; 
Ajabnoor et al., 2018). Besides genetic inheritance, T2DM may be acquired through leading 
a sedentary lifestyle, obesity as well as an increase in age (Bertoglia et al., 2017). Women 
with prior gestational diabetes are also at increased risk for the development of T2DM 
(Herath et al., 2017).   
 
Overweight and obesity aggravate insulin resistance and glucose intolerance  through 
several pathways including hormonal imbalances such as increasing levels of leptin, 
glucagon and cytokines such as interleukin 6 and tumour necrosis factor-α as well as 
decreasing levels of adiponectin (Makki et al., 2013; Rodriguez et al., 2014). Because 
obesity and overweight are major contributors to insulin resistance, insulin sensitivity may be 
increased by increasing physical activity, weight reduction and/or pharmacological treatment 
of hyperglycaemia (American Diabetes Association, 2011).  
 
2.4. Diabetes-induced oxidative stress  
Hyperglycaemia promotes the generation of ROS as a consequence of increased production 
of mitochondrial ROS (Busik et al., 2008; Savu et al., 2011), non-enzymatic glycation of 
proteins (Nawule et al., 2006) and glucose auto-oxidation (Chetyrkii et al., 2011). In the 
absence of an appropriate compensatory response from the antioxidant system, the system 
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becomes overwhelmed by the oxidative effects of ROS and when the balance between 
oxidants and antioxidants derail for whatever reason, loss of equilibrium in favour of oxidizing 
radicals as seen in most cases of diabetes often leads to a phenomenon known as oxidative 
stress (Chikezie et al., 2015).  
Diabetes-induced oxidative stress activates stress sensitive pathways that lead to the 
activation of the protein-kinase C isoforms β, Ϭ and α, increase in the formation of advanced 
glycation end-products (AGEs) and activation of their pathways, increase in glucose flux 
through the polyol pathway, overactivity of the hexosamine pathway as well as decreased 
antioxidant defences (Giacco & Brownlee, 2010; Ceriello, 2011; Safi et al., 2014). Altogether, 
these metabolic pathways converge on the elevation of ROS, ultimately worsening both 
insulin secretion and insulin action and leading to overt T2DM (Yan, 2014). 
 
2.5. Physiological Effects of ROS on Testicular and Epididymal Function  
While spermatozoa are vulnerable to oxidative stress, physiological (low) levels of free 
radicals can contribute to successful spermatogenesis (Saleh et al., 2002). ROS are vital in 
the transduction of signals during spermatogenic biochemical cascades including processes 
of spermatozoal maturation, capacitation, hyperactivation, acrosome reaction, sperm-oocyte 
fusion, maintenance of fertilizing ability and stabilization of the mitochondrial capsule in the 
mid-piece (Kothari et al., 2010; Bansal & Bilaspuri, 2011).  Hence, the concentration of free 
radicals and ROS need to be kept in a state of homeostasi, at levels appropriate to  ensure 
their physiological function while preventing pathological damage.  Figure 2.1 shows the 
physiological and pathophysiological roles of ROS on spermatozoa. 
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Figure 2.1: Physiological and pathological roles of ROS (Kothari et al., 2010). Physiological roles 
of ROS include processes of spermatozoal maturation, capacitation, hyperactivation, acrosome 
reaction and sperm-oocyte fusion. Pathological roles of ROS include spermatozoal membrane lipid 
peroxidation, DNA damage and apoptosis. 
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2.5.1. Maturation  
During the process of spermatozoal maturation, ROS such as hydrogen peroxide (H2O2) 
contribute to the development of a keratinous-like protective coat called the membranous 
capsule around the mitochondria by oxidizing a phospholipid selenoenzyme called 
phospholipid hydroperoxide glutathione peroxidase (PHGPx), to form a chemical 
intermediate capable of forming a selenadisulfide bond with reduced protein thiol groups of 
the capsule (Roveri et al., 2001). When the mitochondrial capsule is assembled, chromatin 
undergoes condensation and motility is acquired for the capacitation of spermatozoa. The 
importance of this mitochondrial capsule lies in the fact that deletion of spermatic 
mitochondrial capsule selenoprotein seriously affects spermatozoal motility despite having 
normal sperm morphology (Baker & Aitken, 2004). 
 
2.5.2. Capacitation 
Capacitation is the penultimate process in spermatozoal maturation that ensures that only 
fertile spermatozoal cells are able to reach, bind and fertilize the oocyte (Baker & Aitken, 
2004; O’Flaherty et al., 2015). During capacitation, spermatozoa physiologically produce 
controlled amounts of ROS for the regulation of downstream events such as the activation of 
protein kinase A and increase in cyclic adenosine 3’, 5’- monophosphate (AMP) with 
subsequent phosphorylation of its substrates (O’flaherty et al., 2004) leading to the 
phosphorylation of MEK-like proteins and threonine-glutamatetyrosine, and finally tyrosine 
phosphorylation of fibrous sheath proteins (de Lamirande & O’flaherty 2008; Kothari et al., 
2010; Chen et al., 2013). Physiological levels of ROS have also been hypothesized to 
enhance spermatozoal capacitation by activating tyrosine kinase, stimulating adenylyl 
cyclase and inhibiting the activities of PTPases. By inhibiting PTPase activity, ROS prevent 
the dephosphorylation and deactivation of phospholipase A2 which cleaves the secondary 
fatty acids from the triglycerol backbone of the membrane phospholipid thereby increasing 
membrane fluidity (Calamera et al., 2003; Khosrowbeygi & Zarghami, 2007; Kothari et al., 
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2010). The increase in cAMP also promotes the hyperactivation of spermatozoa (Agarwal et 
al., 2014).  
 
2.5.3. Hyperactivation   
Increased generation of cAMP via capacitation causes hyperactivation of spermatozoa, 
which is essential for successful fertilization and is considered a subcategory of capacitation 
(Miraglia et al., 2010).  Research shows that the superoxide anion and other ROS such as 
nitric oxide and H2O2 play an essential role in triggering spermatozoal Hyperactivation 
thereby providing spermatozoa with the necessary propulsion to penetrate the cumulus 
oophorous of the oocyte (Kothari et al., 2010; du Plessis et al., 2015). During hyperactivation, 
spermatozoa become highly motile, exhibit high amplitude and an overall increase in side-to-
side head displacement. Spermatozoal motility becomes non-linear with an asymmetric 
flagella movement. As such, hyperactive spermatozoa are capable of penetrating the oocyte 
with a strong propulsive force (Suarez, 2008; Kothari et al., 2010).  
 
2.5.4. Acrosome Reaction  
After successful propulsion of hyperactivated spermatozoa past the cumulous oophorous, 
the capacitated spermatozoa must bind to the zona pellucida (ZP), which is a glycoprotein 
layer that surrounds the oocyte (Sanocka &Kurspisz, 2004; Itach et al., 2012). Capacitated 
spermatozoa must initiate the exocytotic release of proteolytic enzymes on the ZP (de 
Lamirande & O'Flaherty, 2008). Activities of ROS have been shown to increase 
spermatozoal affinity for the ZP. In vitro activation of the acrosome reaction was observed 
when physiological concentrations of the superoxide radical, H2O2, and nitric oxide were 
added to the seminal plasma (Bansal & Bilaspuri, 2011). These ROS activate adenylyl 
cyclase which triggers cAMP to initiate the exocytotic release of proteolytic enzymes thereby 
creating a pore in the extracellular matrix of the ZP (O'Flaherty et al., 1999; Herrero et al., 
2003). 
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2.5.5. Sperm-oocyte Fusion  
After penetration of the ZP, a high degree of spermatic membrane fluidity is essential for 
successful fertilization of the oocyte (Agarwal et al., 2014).  The mechanism by which ROS 
increase membrane fluidity occurs during the processes of capacitation and acrosome 
reaction (Wathes et al., 2007; Kothari et al., 2010). By inhibiting PTPase activity, ROS 
prevent the dephosphorylation and deactivation of phospholipase A2 which cleaves the 
secondary fatty acids from the triglycerol backbone of the membrane phospholipid thereby 
increasing membrane fluidity (Calamera et al., 2003; Khosrowbeygi & Zarghami 2007).  
 
2.6. Pathophysiological effects of ROS on Testicular and Epididymal Function 
Although ROS are crucial for processes of spermatozoal maturation, capacitation, 
hyperactivation, acrosome reaction and sperm-oocyte fusion, their uncontrolled production 
(oxidative stress) produces deleterious effects on spermatozoal biomolecules leading to male 
infertility (Kothari et al., 2010; Bansal & Bilaspuri, 2011; Tvrdá et al., 2011).  In cases where 
the antioxidant defence system is overwhelmed by the high levels of ROS, pathological 
effects result (Chitra et al., 2001). Both current and previous literature have failed to set limits 
that demarcate between physiological and pathological levels of ROS making the 
management of ROS pathological effects a difficulty (Kothari et al., 2010).  
 
Experiments using diabetic patients and experimentally-induced diabetic animal models 
demonstrate that both T1DM and T2DM have detrimental effects on male fertility potentials 
(Agbaje et al., 2007, Mangoli et al., 2013; Ding et al., 2015; Singh et al., 2016). Diabetes-
induced ROS attack testicular and epididymal tissues leading to reduced fertilizing abilites of 
spermatozoa. In testicular tissues, diabetes-induced ROS may disrupt the capacity of the 
germinal epithelium to differentiate into normal spermatozoa as well as reduce normal 
steroidogenic capacity of the leydig cells (Naughton et al., 2001). Diabetes-induced oxidative 
stress can alter testicular morphology, reduce testosterone levels, reduce libido and promote 
retrograde ejaculation (La-Vignera et al., 2012; Jain & Jangir, 2014; Oliveira et al., 2015; 
Elabbady et al., 2016). Diabetes-induced oxidative stress can impair the gonadal antioxidant 
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system thereby leading to testicular and epididymal oxidative damage and hindering 
successful spermatogenesis (Mallick et al., 2007; Hamden et al., 2008). Low levels of 
superoxide dismutase and catalase antioxidant enzymes have been reported in diabetic 
conditions and this has been associated with testicular germinal cell apoptosis (Chatterjee et 
al., 2012). ROS as seen in diabetes mellitus can also oxidize spermatozoal lipids, DNA and 
protein molecules thereby altering cell signalling pathways and enzymatic systems and 
producing irreparable spermatozoal cell alterations, cell death and necrosis (Tvrdá et al., 
2011). Figure 2.2 below shows the impact of diabetes-induced oxidative stress on male 
reproductive function. 
 
 
Figure 2.2: The impact of diabetes-induced oxidative stress on male reproductive function 
(Arokoyo et al., 2017). 
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2.6.1. Lipid Peroxidation 
Diabetes is characterised by high levels of ROS (Asmat et al., 2015). Research shows that 
high levels of testicular and epididymal ROS can oxidize spermatozoal membrane lipids, a 
phenomenon known as lipid peroxidation (LPO) (Sanocka & Kurspisz, 2004; Kothari et al., 
2010; Tvrdá et al., 2011). LPO is the key mechanism for ROS-induced spermatozoal 
damage that leads to male infertility. It impairs spermatozoal membrane function by 
inactivating membrane bound receptors and enzymes, decreasing the fluidity of 
spermatozoal membranes and increasing non-specific permeability to ions (Sanocka & 
Kurspisz, 2004). The susceptibility of spermatozoal membranes to LPO lies in the fact that 
the lipid membranes are largely composed of polyunsaturated fatty acids (PUFA) (Agarwal & 
Saleh, 2002; Bansal & Bilaspuri, 2011). The presence of the double bond in PUFA makes 
spermatozoal membranes prone to oxidative attack (Bucak et al., 2010). 
Oxidative attack on spermatozoal lipids initiate the LPO cascade, which is an autocatalytic, 
self-propagating reaction capable of precipitating cellular dysfunction associated with loss of 
membranal function and integrity (Bansal & Bilaspuri, 2010; Agarwal et al., 2014).  The LPO 
cascade can be divided into 3 phases namely the initiation phase, propagation phase and 
termination phase (Tremellen, 2008; Kothari et al., 2010). Before the cascade can be 
initiated, ROS energetic enough to initiate the cascade must be generated. The superoxide 
free radical is the predominant ROS generated within the spermatozoa. It can react by itself 
via dismutation to generate H2O2. Depending on the availability of transition metals such as 
iron (Fe) or copper (Cu), the superoxide free radical and H2O2 can undergo the Haber-Weiss 
reaction to generate the highly pernicious hydroxyl radical (OH•) (Badade & Samant, 2011). 
Alternatively, in the presence of a reducing agent such as ferrous ions or ascorbate, OH• 
radicals can be generated from H2O2, via the Fenton reaction. The presence of OH• radicals 
mark the initiation phase as these radicals are energetic enough to initiate the LPO cascade 
(Sikka, 2001; Hazout et al., 2008; Chen et al., 2013). 
 
The initiation phase is characterized by hydrogen abstraction of PUFA by potent initiators of 
the LPO cascade such as the OH• radicals (Ayala et al., 2014). Thereafter, the propagation 
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phase follows which is characterized by the formation of lipid alkyl radicals which rapidly 
react with molecular oxygen leading to the formation of lipid peroxyl radicals. Lipid peroxyl 
radicals are energetic enough to abstract a hydrogen atom from PUFA leading to the 
formation of another lipid radical and lipid hydroperoxides (Ogbuewo et al., 2010). Because 
the peroxyl and alkyl radicals are generated in a cyclical fashion, they continue to oxidize 
lipid membranes indefinitely until one of the substrates is consumed or until the LPO cascade 
is terminated by a radical-to-radical reaction to form a stable product during the termination 
phase (Agarwal & Saleh, 2002; Sanocka & Kurspisz, 2004).  Because LPO is self- 
propagating, approximately 60% of PUFA can be lost from the spermatozoal lipid 
membranes leading to increased non-specific permeability to ions, inactivation of membrane 
bound receptors and enzymes and subsequent loss of fluidity (Agarwal et al., 2014). 
 
2.6.2. DNA damage  
ROS have the potential to damage both spermatozoal nuclear DNA and mitochondrial DNA 
(mtDNA), however, research shows that mtDNA is more susceptible to oxidative stress 
because it is naked (Kumar et al., 2009).  Human spermatozoal nuclear chromatin is highly 
condensed and organized. It is packed into nucleosomes and coiled into solenoids (Arpanahi 
et al., 2009). During spermatogenesis, the chromatin is modified by replacing histones with 
transition proteins and protamines (Miller et al., 2010). The strands of DNA are condensed by 
the protamines and form the basic packaging unit of spermatozoal chromatin known as the 
toroid which is further compacted by intra- and inter- molecular disulphide bridges (Bennetts 
& Aitken, 2005). This intricate compaction and organisation shields spermatozoal chromatin 
from oxidative damage, conferring resistance against ROS-induced DNA damage (Agarwal 
et al., 2014). However, some areas of poor compaction and incomplete protamination do 
exist and these are vulnerable to the effects of oxidative stress. These areas suffer base 
modifications, deletions, base-free sites, DNA crosslinks, frame-shift mutations, point 
mutations as well as chromosomal rearrangements (Agarwal et al., 2003; Schulte et al., 
2010; Spiropoulos et al., 2002). 
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In contrast to the highly organized and protaminated nuclear DNA, mtDNA is not bound by 
histones making it more vulnerable to the effects of ROS (Sawyer & Aitken, 2001). 
Mitochondrial genome mutations can result in the production of excessive amounts of ROS 
that can disturb the formation of morphologically and functionally mature spermatozoal cells 
thus leading to male factor infertility (Saalu, 2010). MtDNA mutations may also cause a 
defect in mitochondrial energy metabolism (Chinney & Turnbull, 2000); hence, lower levels of 
mutant mtDNA may compromise sperm motility (Spiropoulos et al., 2002). González-Marín et 
al, (2012) reported that in humans, approximately 80% of structural chromosome aberrations 
are of paternal origin. Spermatozoal DNA damage leads to apoptosis, poor fertilization rates, 
high frequency of miscarriages and morbidity in offspring (Chen et al., 2013). 
 
2.6.3. Apoptosis  
Apoptosis is a natural physiological process by which the body gets rid of old, senescent 
cells including abnormal germ cells thereby preventing their overgrowth during 
spermatogenesis (Agarwal & Allamaneni, 2006). Apoptosis is a non-inflammatory response 
to tissue damage characterised by a series of morphological and biochemical modifications 
that promote controlled cell death (Majai et al., 2006; Davidovich et al., 2014). High levels of 
ROS promote spermatozoal apoptosis thereby playing an important role in the development 
of male infertility (Agarwal & Allamaneni, 2006). 
 
Mitochondria are important generators of spermatozoal ROS and their activity become 
enhanced when spermatozoal cells become apoptotic.  As such, the generation of ROS by 
mitochondria is one of the early signs that spermatozoal cells have engaged the intrinsic 
apoptotic cascade (Koppers et al., 2011).  High levels of ROS as seen in diabetic situations 
are capable of disrupting the inner and outer mitochondrial membranes thereby stimulating 
the release of cytochrome C that in turn signals the release of caspases 3 and 9 which 
induces apoptosis (Agarwal et al., 2008). In most cases, increased spermatozoal damage by 
ROS is associated with higher levels of cytochrome C and caspases 3 and 9 indicating that 
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ROS-induced apoptosis is a significant male factor of infertility (Agarwal et al., 2008). A study 
by Said et al, (2004) revealed that the HOCI radical, formed from H2O2 and chloride ions, is 
associated with high levels of spermatozoal apoptosis.   
 
2.6.4. Oxidative damage to proteins  
The structure and function of proteins is susceptible to oxidative damage by ROS (Tvrdá et 
al. 2011). Proteins have many side chain targets that are susceptible to the oxidative effects 
of ROS e.g. cysteine, methionine, and tyrosine (Tiwari et al., 2013). By producing free 
radicals, diabetic hyperglycaemia can lead to protein glycation and oxidative degeneration 
(Asmat et al., 2015). ROS attack on proteins result in site-specific amino acid modifications, 
fragmentation of the peptide chain, altered electric charge, aggregation of cross-linked 
reaction products, and increased susceptibility to proteolysis (Tvrdá et al. 2011). High levels 
of protein carbonyls have been reported in a variety of cells and plasma in diabetic patients 
(Pandey et al., 2010). Oxidative damage to protein may also alter the structure and function 
of antioxidant enzymes.  Altered enzymes cannot perform their antioxidative role hence ROS 
accumulate without detoxification leading to the enhancement of oxidative stress in diabetic 
conditions (Maritim et al., 2003). 
 
2.7. Testicular and Epididymal Antioxidants  
ROS are necessary for spermatozoa to achieve functional competence; hence ROS should 
be maintained at concentrations not deleterious to spermatozoa (Saleh et al., 2002). An 
antioxidant is defined as any substance whose availability, even in minute concentrations 
inhibits or delays the oxidation of a substrate (Somogyi, 2007). Antioxidants are capable of 
disposing, scavenging and suppressing the formation of ROS or oppose their actions (Bansal 
& Bilaspuri, 2011). The testes, epididymis, seminal plasma and spermatozoa contain an 
elaborate array of both enzymatic and non-enzymatic antioxidants to ensure spermatogenic 
and steroidogenic functions are not impacted by oxidative stress (Fujii et al., 2003; Garrido et 
al., 2004a; Aitken & Roman, 2008). These antioxidant defence systems are of great 
importance as peroxidative damage is currently regarded as one of the most important 
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causes of impaired testicular function (Aitken & Roman, 2008). Besides classifying 
antioxidants as either enzymatic or non-enzymatic, antioxidants can further be subdivided 
into fat-soluble or water-soluble antioxidants. Fat soluble antioxidants are located in cellular 
membranes and lipoproteins e.g. Vitamin E, β-carotene and coenzyme Q-10 while water-
soluble antioxidants are found in extracellular and intracellular fluids e.g. Vitamin C, 
glutathione peroxidase, superoxide dismutase and catalase (Ogbuewo et al., 2010). 
 
2.7.1. Enzymatic Antioxidants 
There are three main types of enzymatic antioxidants in spermatozoa namely superoxide 
dismutase, catalase and glutathione peroxidase antioxidant enzymes. These play a 
significant role in decomposing ROS in spermatozoal cells (Tremellen, 2008). 
 
2.7.1.1. Superoxide Dismutase (SOD) 
These are metal-containing enzymes that catalyse the conversion of 2 superoxide radicals 
into molecular oxygen and H2O2 which is less toxic than the superoxide radical. In this 
manner, SOD protects spermatozoa against oxygen toxicity (Agarwal et al., 2004; Aitken & 
Roman, 2008). The anti-lipoperoxidative defence system in human spermatozoa relies 
almost entirely on the dimeric copper-zinc isoform of SOD (Cu-Zn SOD). This isoform is 
localized in the cytosol and inter-membranal space of spermatozoa. In addition to  the Cu-Zn 
SOD, there are 2 other SOD isoforms namely the manganese SOD (Mn-SOD) and 
extracellular SOD (EC-SOD) which are located in the mitochondria and extracellular space 
respectively (Mruk et al., 2002;; Badade & Samant, 2011). 
 
2.7.1.2. Catalase  
Catalase is a common enzymatic antioxidant found in most living organisms that are 
exposed to oxygen. It plays a significant role against oxidative stress-generated 
complications such as is seen in diabetes mellitus. H2O2 molecules generated during energy 
metabolism are powerful oxidants that must be rapidly eliminated from the cell before they 
induce oxidative damage to cellular lipids, DNA and protein molecules (Tiwari et al., 2013). 
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Catalase regulates H2O2 metabolism by enzymatically processing it into oxygen and water 
molecules thereby neutralising it and completing the reaction started by SOD (Asmat et al., 
2015). Catalase is usually located in cellular organelles called peroxisomes and is efficient at 
an optimum temperature of 370C. Its turnover is among the highest in comparison to other 
enzymes with reports stating that a single catalase molecule is capable of converting millions 
of H2O2 molecules into water and molecular oxygen per second (Badade & Samant, 2011). 
 
2.7.1.3. Glutathione peroxidase  
Glutathione peroxidase (GPx) constitutes a family of enzymatic antioxidants involved in the 
reduction of hydroperoxides using glutathione as an electron donor (Tremellen, 2008). GPx 
enzymes are present within spermatozoa, seminal plasma, the testis, seminal vesicles, 
prostate as well as the epididymis (Vernet et al., 2004). In differentiating spermatozoa, GPx 
is mostly located in the mitochondrial region, nucleus and acrosomal domains (Vaisberg et 
al., 2005). GPx enzymatically reduce lipid hydroperoxides into their corresponding alcohols 
and detoxifies H2O2 into water molecules (Badade & Samant, 2011).  
 
In the testicular context, the phospholipid hydroperoxides glutathione peroxidase (PHGPx) 
isoform is highly expresses in both leydig and spermatogenic cells. Baek et al, (2007) and 
Foresta et al, (2002) reported a direct relationship between male fertility and PHGPX levels. 
In addition to protecting spermatozoal membranes against peroxides, GPx also permits the 
regeneration of spermatozoal membrane lipid molecules (Ogbuewo et al., 2010). Scientific 
research has correlated a reduction in spermatozoal and seminal plasma GPx activity with 
male factor infertility (Giannattasio et al., 2002; Garrido et al., 2004b).  
 
Continued GPx activity depends on the reduction of glutathione by an enzyme called 
glutathione reductase (Labuschagne et al., 2013). Inhibition of glutathione reductase affect 
GPx activity by reducing the availability of reduced glutathione thereby exposing 
spermatozoa to the effects of oxidative stress (Williams & Ford, 2004). In this manner, the 
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co-ordinated activities of GPx, glutathione reductase and glutathione (as an electron donor) 
protect spermatozoa against oxidative attack (Dinesh et al., 2012).  
 
2.7.2. Non-enzymatic antioxidants 
While the testicles clearly do possess highly specialized antioxidant defence enzymes such 
as SOD, catalase and GPx, they also rely on small molecular weight, non-enzymatic 
antioxidants (Aitken & Roman, 2008). The antioxidative function of these non-enzymatic 
molecular antioxidants is particularly important in the extracellular space where enzymatic 
antioxidants are absent or are present in minute quantities (Ogbuewo et al., 2010).  There 
are benefits associated with treating susceptible individuals with exogenous, small molecular 
weight, non-enzymatic antioxidants. Non-enzymatic antioxidants such as Vitamin C, Vitamin 
E, zinc, selenium, glutathione, cysteine, melatonin, coenzyme Q-10, carotenoids and 
carnitine can be acquired from consuming certain fruits and vegetables (Aitken & Roman, 
2008; Lampiao, 2012).   
 
2.7.2.1. Vitamin C (Ascorbic Acid) 
Vitamin C is an important water-soluble, non-enzymatic, chain-breaking antioxidant capable 
of neutralizing OH• and superoxide radicals as well as H2O2 in extracellular areas of the body 
e.g. seminal plasma (Agarwal et al., 2004; Ogbuewo et al., 2010). The concentration of 
Vitamin C in seminal plasma is reported as being 10× greater than that in blood plasma. 
Vitamin C can prevent LPO, recycle oxidized Vitamin E and protect against H2O2 -induced 
DNA damage (Agarwal et al., 2007; Badade & Samant, 2011). As such, Vitamin C plays a 
significant role (up to 65%) in combatting oxidative stress in seminal plasma (Sharma & 
Agarwal, 1996).  
 
2.7.2.2. Vitamin E  
Vitamin E, also known as α-tocopherol, is a potent lipophilic, non-enzymatic antioxidant 
which is vital in the protection of mammalian spermatozoa against the effects of oxidative 
stress (Asadi et al., 2017). The structure of Vitamin E is characterized by the presence of a 
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benzene ring and a long hydrocarbon chain, making it hydrophobic in nature (Ogbuewo et 
al., 2010). As such, α-tocopherol is located in biological membranes and lipoproteins where it 
traps and scavenge ROS such as the superoxide radical, OH• radical and H2O2 (Agarwal et 
al., 2004). Because it can directly quench free radicals generated during the LPO cascade 
such as the peroxyl and alkoxyl radicals, Vitamin E is considered a major chain-breaking 
antioxidant and appears to have a dose-dependent effect (Bolle et al., 2002; Badade & 
Samant, 2011).  
 
2.7.2.3. Glutathione 
Glutathione is a tripeptide molecule (glutamyl-cysteine-glycine) that is an important cofactor 
of GPx, an enzymatic antioxidant that catalyses the reduction of toxic H2O2 and other 
hydroperoxides (Uysal & Bucak, 2007). On the other hand, reactions with ROS oxidize 
reduced glutathione (GSH) into oxidised glutathione (GSSG). However, once oxidized, 
glutathione is reduced in a redox cycle involving glutathione reductase and an electron 
acceptor (Nistiar et al., 2009). On that note, testicular and epididymal GSH and GPx act as 
reducing agents thereby protecting lipid constituents against peroxidative damage and 
preserving sperm viability and motility (Lanzafame et al., 2009; Mora-Esteves & Shin, 2013). 
 
2.7.2.4. Selenium 
In the testis, most of the selenium is incorporated within PHGPx, where it forms part of the 
catalytic centre of this antioxidant enzyme (Ogbuewo et al., 2010). PHGPx protects 
liposomes and biomembranes from LPO and exhibits GPx activity on phosphatidylcholine 
hydroperoxides. PHGPx is able to react with hydroperoxides of fatty acids esterified in the 
phospholipids and use protein thiol groups as donor substrates (Hermesz & Ferencz, 2009; 
Said et al., 2010). Selenium deficiency is often associated with reduced testicular mass, 
destabilization of the spermatozoal midpiece and affects the overall morphology of 
spermatozoa (Garrido et al., 2004b).  
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2.7.2.5. β-carotene 
β-carotene is a non-enzymatic antioxidant that occurs naturally in apricots and carrots (El-
Demerdash et al., 2004). It is known to possess pro-vitamin A activity and antioxidative 
properties (Vardi et al., 2009). Like tocopherol, β-carotene is a lipid-soluble antioxidant, a 
characteristic that enables it to easily permeate through biological membranes; however, its 
antioxidant strength is weaker than that of α-tocopherol and will only be used as an 
antioxidant after all other antioxidant defences have been exhausted (Ogbuewo et al., 2010). 
Because of its non-polar nature, β-carotene is located in spermatozoal membranes and 
lipoproteins and is effective in reducing lipid-derived free radicals and quenching singlet 
oxygen molecules (El-Demerdash et al., 2004; Vardi et al., 2009; Ogbuewo et al., 2010).  
 
2.7.2.6. Cysteine  
Cysteine (N-acetyl-cysteine) is a naturally occurring low-molecular weight amino acid which 
functions as a seminal antioxidant and precursor of intracellular glutathione (glutamyl-
cysteine-glycine) (Uysal & Bucak, 2007; Mistry et al., 2012). The cysteine subunit of 
glutathione provides and exposes a sulfhydryl group that directly scavenges free radicals 
(Badade & Samant, 2011; Tvrdá et al. 2011). By scavenging free radicals, cysteine protects 
spermatozoal membrane lipids and proteins against peroxidative damage (Hendin et al., 
1999).  
 
2.7.2.7. Zinc 
Zinc (Zn) is a potent, non-enzymatic antioxidant and a main component of free radical-
inhibiting enzymes such as Cu-Zn SOD (Asadi et al., 2017).  Zn also serves as a catalyst 
that prevents LPO by relocating and transferring metals including iron and copper from 
catalytic sites (Sikka, 2001). 
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2.7.2.8. Carnitine 
L-carnitine or 3-aminobutyric acid is a naturally-occurring, vitamin-like, non-enzymatic 
antioxidant (Lenzi et al., 2004), that is found in high concentrations within the epididymis 
where its concentration has been reported as being 2000 times higher than in whole blood 
(Enomoto et al., 2002; Arduini et al., 2008). It prevents LPO by scavenging free radicals 
(Lenzi et al., 2004).  Apart from its antioxidant properties, research also acknowledges the 
antiapoptotic effects of carnitine, its ability to promote spermatozoal maturation as well as its 
function as an energy provider within the male reproductive tract (Ng et al., 2004; Steibar et 
al., 2004; Dokmeci, 2005). 
 
2.7.2.9. Melatonin 
Melanin (N-acetyl-5-methoxytryptamine) is a pineal hormone that is crucial in the protection 
against testicular oxidative stress (Aitken & Roman, 2008). The antioxidant effects of 
melatonin on the testis are supported by findings by, Mogulkoc et al, (2006), who reported 
that rats that underwent pinealoctomy suffered significant testicular oxidative damage. 
Additionally, unlike other free-radical scavengers that undergo one electron oxidation; when 
melatonin acts as an antioxidant, it undergoes a two electron oxidative process making it 
readily attractive to free radicals, as well as giving it an added advantage of not redox-cycling 
and inadvertently generating free radicals (Aitken & Roman, 2008; Asadi et al., 2017). 
 
2.7.2.10. Cytochrome C 
Cytochrome C is a small molecular mass, non-enzymatic antioxidant that can effectively 
scavenge free radicals such as H2O2. It is also a powerful activator of apoptosis that 
increases the protective capacity of testicular tissue by eliminating damaged germ cells (Liu 
et al., 2006). 
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2.7.2.11. Coenzyme Q-10 
Coenzyme Q-10 (CoQ10) alternatively known as ubiquinone, is a potent lipophilic, naturally 
occurring, non-enzymatic antioxidant related to low-density lipoproteins that is capable of 
protecting spermatozoa against LPO (Mazen & Elgris, 2013; Ogbuewo et al., 2013; Asadi et 
al., 2017). It is also essential in the regeneration and recycling of Vitamin E (Karbownik et al., 
2001) and is a cofactor in the mitochondrial respiratory chain and in ATP production (Mazen 
& Elgris, 2013). Because CoQ10 has energy-promoting properties, it enhances spermatozoal 
motility and is therefore present in large quantities in the spermatozoal midpiece (Karbownik 
et al., 2001). 
 
2.8. Management of diabetes mellitus-related sexual dysfunction 
Once an individual has been identified as having oxidative stress-related infertility, treatment 
should be aimed at the identification and amelioration of the underlying cause before 
considering antioxidant treatment (Tremellen, 2008). Lifestyle behaviours such as smoking, 
poor diet, alcohol abuse, obesity or psychological stress have all been linked with oxidative 
stress and eliminating these lifestyle triggers for oxidative stress by making positive lifestyle 
changes such as a diet high in fruit and vegetables, maintenance of normal weight and a 
reduction in smoking and alcohol intake can at least have some beneficial effects on 
spermatozoal health (Tremellen, 2008; Dinesh et al., 2012). 
 
High blood glucose levels as seen in diabetic conditions promote the generation of ROS and 
in the absence of an appropriate compensatory response from the antioxidant system, 
oxidative stress results, which is the main cause of diabetes secondary complications 
(Maritim et al., 2003) including sexual dysfunction (Van belle et al., 2011; Oliveira et al., 
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2015). By increasing the production of ROS and LPO in testicular and epididymal tissues, 
diabetes may contribute to male infertility. 
 
The first step in the management of diabetes-induced male infertility must therefore be the 
management of the underlying diabetic condition. By controlling blood glucose levels and 
increasing antioxidant capacity, levels of oxidative stress can be reduced (Singh et al., 2013). 
Although the use of synthetic hypoglycaemic agents has improved the outlook of diabetic 
patients, many of them harbour serious adverse effects, are expensive, require expertise 
(Modak et al., 2007) and some of them have done little to control secondary complications of 
diabetes. To date, the management of diabetes without side effects remains a challenge and 
the search for alternative remedies such as medication from natural products is paramount 
(Saxena & Kishore, 2004). 
 
2.9. Pharmacological Management of Diabetes 
Because T1DM is characterised by the absence or inadequate production of insulin, 
treatment is focused on introducing insulin so as to control blood glucose levels. As such, 
exogenous insulin therapy is the main pharmacological treatment option in the management 
of T1DM (Sheeja et al., 2010). With regards to T2DM, besides diet modulation and physical 
exercise to reduce weight and abdominal fat; the use of hypoglycaemic agents with different 
modes of action such as biguanides, incretin mimetics, sulfonylureas, meglitinides, 
thiozolinedione, bromocriptine, α- glycosidase inhibitors and sodium-glucose cotransporter-
inhibitors are used for the treatment of type 2 diabetic patients (Siddiqui et al., 2013). Figure 
2.3 outlines mechanisms of action of various antidiabetic drugs for the management of 
T2DM. 
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Figure 2.3: Mechanism of action of various antidiabetic drugs for the management of T2DM 
(Evans et al., 2016) 
 
2.9.1. Insulin Therapy 
Exogenous insulin is the mainstay of T1DM treatment and can also be used in cases where 
T2DM progresses to a state of β-cell failure with little or no insulin production (Sheeja et al., 
2010; Chaudhury et al., 2017). A variety of beef, pork and pork/beef insulin were previously 
used as insulin regimens; however recombinant human insulin is now used almost 
exclusively especially in the United States of America (Khardori, 2008). Insulin is 
administered by means of subcutaneous injections, insulin pumps or insulin pens in basal 
and bolus schemes (Schaschkow et al., 2016). There are 4 main categories of insulin namely 
rapid-acting, short-acting, intermediate-acting and long-acting insulin. The difference 
between these insulin categories is based on their onset of action, peak-action and duration 
of action (Khardori, 2008).  
Rapid-acting insulin e.g. Lispro and glulisine are absorbed more quickly and have a rapid 
onset of action (within 15 minutes), peaks 30-90 minutes after injection and have a short 
duration of action (4-5 hours). Short-acting insulin, e.g. regular insulin, reaches blood within 
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30 minutes, peaks 2-4 hours after injection and is active for 4-8 hours. Intermediate-acting 
insulin e.g. Neutral Protamine Hagedorn have a slower onset of action as compared to 
regular insulin and reaches blood 2-6 hours following injection. Peak action occurs 4-14 
hours after dosage and its effects last for 14-20 hours. Long acting insulin e.g. glargine have 
no peak action and produces stable insulin levels for more than 24 hours (Sheeja et al., 
2010).  
 
2.9.1.1. Challenges of Insulin Therapy 
Despite the fact that insulin therapy can significantly lower levels of glycated haemoglobin 
several patient, physician and health-care system barriers negatively influence its usage 
(Linetzky et al., 2016). With regards to patient barriers, factors such as injection phobia, fear 
of hypoglycaemic events, perceived lack of efficacy, mentality that insulin therapy may have 
a negative impact on their lifestyle as well as fear of gaining weight, may make patients 
reluctant to initiate insulin therapy (Peyrot et al., 2005). Besides the fact that insulin therapy 
is a time consuming and expensive treatment option, physicians also fear for the safety of 
their patients especially the possibility of weight gain and hypoglycaemic events (Oish et al., 
2011; Ross et al., 2011). Sometimes physicians are reluctant to initiate insulin therapy for 
some patients because of the fear that those patients may fail to comply due to inadequate 
patient understanding of how complex insulin regimens are (Philis-Tsimikas, 2013). 
Healthcare system barriers such as limited access to medical care and out-of-pocket 
expenditures may also limit the consideration of insulin therapy (Wallace & Mathews, 2000; 
McEwen et al., 2009). 
2.9.2. Biguanides (Metformin) 
Across all age groups, T2DM is managed by use of metformin, a drug classified as a 
biguanide (Chaudhury et al., 2017). Metformin is the first line oral drug of choice in the 
management of T2DM because of its effectiveness in reducing levels of blood glucose with 
minimum risk of hypoglycaemia (Siddiqui et al., 2017). It has been reported that metformin is 
capable of delaying the progression of T2DM as well as reducing mortality amongst these 
 29
patients (Viollet et al., 2012). Metformin decreases hepatic glucose synthesis and sensitizes 
the liver to the effects of insulin by activating insulin receptor expression and enhancing 
tyrosine kinase activity (Chaudhury et al., 2017). It activates AMP-activated protein kinases 
in the liver thereby promoting hepatic glucose uptake and inhibiting gluconeogenesis by 
influencing activities of mitochondrial enzymes (Viollet et al., 2012). 
 
2.9.2.1. Challenges of Metformin 
Although metformin has a relatively safe profile in comparison to most other hypoglycaemic 
agents, it is contraindicated in patients with advanced renal insufficiency (Inzucchi et al., 
2014). The use of metformin has also been reported to cause gastrointestinal disturbances in 
form of diarrhoea, dyspepsia and nausea in an estimated 30% of subjects (Valeron & de 
Pablos-Velasco, 2013). Research has also revealed that metformin is highly efficient when 
there is adequate insulin production; however, its efficacy decreases as T2DM progresses to 
a state of β-cell failure with little or no insulin production (Chaudhury et al., 2017). 
 
2.9.3. Sulfonylureas 
By blocking potassium ATP channels (kATP channels); sulfonylureas increase the secretion 
of insulin by the pancreas thereby lowering levels of glucose in the blood (de Wet & Proks, 
2015). This class of drugs binds to specific sites on the kATP channel complex thereby 
inhibiting the activity of this channel and leading to cell membrane depolarisation and a 
cascade of activities that promote the secretion of insulin (Siddiqui et al., 2013).  
2.9.3.1. Challenges of Sulfonylureas  
Hypoglycaemia is the major drawback with regards to the usage of sulfonylureas (Valeron & 
de Pablos-Velasco, 2013); hence, the use of long-acting sulfonylureas is discouraged in 
elderly patients as well as patients with issues of alcohol abuse and poor nutritional status 
(Siddiqui et al., 2013). This class of drugs must also be used with caution in patients using β-
blockers as these prolong the effects of sulfonylureas (May & Schindler, 2016). Minor side 
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effects associated with this class of drugs include hypersensitivity reactions, headaches, 
dizziness and gaining of weight (Chaudhury et al., 2017).  
 
2.9.4. Meglitinides 
Meglitinides (e.g. repaglinide and nateglinide) are non-sulfonylureas insulin-secretagogues 
that control postprandial hyperglycaemia by binding to the sulfonylureas receptor in the β- 
cells of the pancreas in the same way as sulfonylureas (Mendoza et al., 2013); however, the 
binding of meglitinides is weaker than that by sulfonylureas hence meglitinides are regarded 
as short-acting insulin secretagogues giving them flexibility in terms of administration 
(Dornhorst, 2001). Although meglitinides have a rapid onset of action, its duration of action is 
relatively short (Brickle et al., 2006). However, because the risk of hypoglycaemia is less 
than that of sulfonylureas, meglitinides are more preferable in the management of diabetic 
patients with chronic kidney disease and those who cannot tolerate sulfonylureas and 
metformin (Siddiqui et al., 2013). 
 
2.9.4.1. Challenges of Meglitinides 
Higher levels of blood glucose must first be reached before meglitinides can stimulate the 
secretion of insulin by the β- cells of the pancreas making them less effective in the 
management of diabetes as compared to sulfonylureas (Chaudhury et al., 2017). In addition, 
the need for multiple dosages may reduce compliance in patients using meglitinides 
(Inzucchi, 2002). 
 
2.9.5. Incretin mimetics 
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are 
naturally occurring, short-lived incretin hormones that play an important role in the 
maintenance of glycaemic control by enhancing the synthesis and release of insulin from 
pancreatic β-cells and decreasing the release of glucagon from pancreatic β-cells (Siddiqui et 
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al., 2013). Because GIP and GLP-1 are rapidly degraded by the dipeptidyl peptidase-4 (DPP-
4) enzyme, they have short half-lives (Meneilly et al., 2000; Drucker, 2006). 
 
The incretin effect is responsible for the secretion of 50-70% of total insulin after oral glucose 
intake (Nauck & Meier, 2016). In T2DM conditions, the incretin effect is reduced or absent 
since the insulinotropic action of GIP is lost in these patients (Holst et al., 2011). Two drug 
classes namely the GLP-1 agonists (e.g. exenatide and liraglutide) and DPP-4 inhibitors (e.g. 
sitagliptin, saxagliptin, linagliptin, alogliptin and vidagliptin) are currently in use (Messori et 
al., 2014; Andreozzi et al., 2016). These drugs improve glycaemic control while reducing 
weight and systolic blood pressure in T2DM patients. As such, insulin mimetics are finding 
increased usage in the management of patients with T2DM (Maruthur et al., 2016; 
Chaudhury et al., 2017).  
 
2.9.5.1. Challenges of Incretin Mimetics 
Treatment with GLP-1 agonists such as exenatide has been associated with gastric 
discomfort that in many cases has led to discontinuation of medication (Valeron & de Pablos-
Velasco, 2013). Liraglutide has been associated with nausea and minor hypoglycaemia 
(Marre et al., 2009). On the other hand, usage of DPP-4 inhibitors has been associated with 
upper respiratory tract infections, nasopharyngitis and headaches (Pathak & Bridgeman, 
2010). Acute pancreatitis was also reported in a fraction of patients treated by sitagliptin as 
monotherapy or in combination with metformin (Chaudhury et al., 2017).  
 
 
2.9.6. Thiozolinediones   
Thiozolinediones (TZDs) e.g. rosiglitazone, pioglitazone and troglitazone (Sanchez et al., 
2006) are insulin sensitizers that act as Peroxisome Proliferator Activator Receptor (PPAR)-
agonists thereby reducing insulin resistance in peripheral tissues such as the muscle and 
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adipose tissues (Chiarelli & Di-Marzio, 2008). They decrease hepatic gluconeogenesis and 
facilitate increased glucose uptake by tissues of the liver, muscle and adipose tissue (Yoon 
et al., 2009). TZDs have also been reported to reduce inflammatory cytokines and increase 
levels of adiponectin thereby improving β-cell integrity and function. In this manner, TZDs 
improve insulin sensitivity and pancreatic β-cell function (Powers & D’Alessio, 2011; 
Chaudhury et al., 2017). 
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2.9.6.1. Challenges of Thiozolinediones   
Hepatotoxicity has been reported in an estimated 2% of patients using TZDs as early as 35 
days and as late as 8 months after onset of therapy. As such monthly monitoring of 
transaminase and bilirubin levels is crucial in the first 8 months of therapy (Mahler & Adler, 
1999). Additionally, the risk of peripheral oedema and dilutional anaemia has been reported 
among patients using TZDs; hence, limiting its use in patients with renal disease (Mahler & 
Adler, 1999; Mudaliar et al., 2003; Horita et al., 2015). The usage of pioglitazone has been 
associated with an increased risk for weight gain, oedema, heart failure, bladder cancer and 
distal bone fractures in post-menopausal women (Valeron & de Pablos-Velasco, 2013).  
 
2.9.7. Alpha -glucosidase inhibitors (AGIs) 
Retarding the absorption of glucose by inhibiting enzymes that hydrolyse carbohydrates is an 
effective therapeutic approach in the management of T2DM and impaired glucose tolerance 
(Kim et al., 2008; Van de Laar, 2008). Alpha-glucosidases are membrane-bound enzymes 
localised in the epithelium of small intestines that catalyse the breakdown of complex dietary 
carbohydrates into absorbable monosaccharaides such as glucose (Kumar et al., 2011). 
AGIs slow down the breakdown of carbohydrates into glucose by inhibiting α-glucosidase 
enzymes, thereby reducing post-prandial glucose levels and suppressing post-prandial 
hyperglycaemia (Bukhari et al., 2017).  
 
2.9.7.1. Challenges of AGIs 
Major side effects associated with the usage of AGIs come as a consequence of undigested 
carbohydrates reaching the colon where they are fermented by bacteria. Patients using AGIs 
suffer from abdominal discomfort, bloating and flatulence (Dabhi et al., 2013). Because of 
these gastrointestinal side effects, compliance has become a problem amongst AGI users. 
On the other hand, AGIs are relatively expensive in comparison to sulfonylureas and the 
need for 3 daily dosages might affect compliance amongst AGI users. (Van de Laar, 2008). 
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2.9.8. Sodium-glucose co-transporter-inhibitors  
With the growing knowledge concerning the importance of the kidneys in maintaining glucose 
homeostasis, the development of a new set of drugs that target the kidneys in the treatment 
of diabetes has emerged (Nauck, 2014). Sodium-glucose co-transporters (SGLT2) facilitate 
the reabsorption of glucose in the kidneys (Chao & Henry, 2010). Inhibiting SGLT2 
decreases renal reabsorption of glucose resulting in enhanced urinary excretion of glucose 
and subsequent reduction in levels of glucose and glycated haemoglobin in plasma 
(Ferrennini & Solini, 2012; Nauck, 2014). Because SGLT2-inhibitors enhance urinary 
excretion of glucose, its usage is associated with weight loss. As such SGLT2-inhibitors are 
viewed as an attractive therapeutic alternative for T2DM patients who are not benefiting from 
metformin monotherapy especially if weight is part of the underlying treatment consideration. 
In addition to this, the mechanism of action of SGLT-2 inhibitors does not rely upon insulin 
sensitivity or β-cell dysfunction making it possible to use this drug with other antidiabetic 
agents including insulin (Nauck, 2014). 
 
2.9.8.1. Challenges of SGLT2-inhibitors 
Side effects following the usage of SGLT2-inhibitors are related to high levels of glucose in 
urine. Patients on SGLT2-inhibitors experience genital mycotic infections and urinary tract 
infections (Nauck, 2014). In May of 2015, the Food and Drug Administration organisation 
warned that treatment with SGLT2-inhibitors may increase the risk of ketoacidosis in both 
T1DM and T2DM patients (Food and Drug Administration, 2015).  
 
2.9.9. Bromocriptine 
Bromocriptine is a sympatholytic, D2-dopamine agonist used in the treatment of T2DM 
(DeFronzo, 2011). This class of drugs is derived from an ergot alkaloid and has been in 
clinical use for over 30 years (Colao et al., 2006; Kvernmo et al., 2006). Glucose and energy 
metabolism is tightly controlled by the central nervous system (CNS) through sympathetic 
pathways (Sandoval et al., 2008). By activating CNS dopaminergic pathways, dopamine 
agonist therapy with bromocriptine regulates the production of hepatic glucose and integrates 
 35
information on fuel availability through hormonal signals such as insulin, GLP-1, leptin and 
ghrelin (Via et al., 2010). Because diabetic patients have impaired response to these 
pathways; they present with elevated hepatic glucose production, insulin resistance and β-
cell dysfunction.  
The modulation of neurotransmitter action in the brain by bromocriptine has been shown to 
improve insulin sensitivity as well as glucose tolerance using obese and diabetic animals as 
experimental models (Pijl et al., 2000).  Quick release-bromocriptine may be used as 
monotherapy or in combination with insulin and other hypoglycaemic agents in the 
management of T2DM patients with mild hyperglycaemia characterised by glycated 
haemoglobin levels close to 7.5% (Nasser, 2011; Siddiqui et al., 2013).  The addition of 
bromocriptine in poorly controlled T2DM patients treated by sulfonylureas and metformin 
alone decreases glycated haemoglobin levels by 0.5-0.7 (DeFronzo, 2011).  
 
2.9.9.1. Challenges of Bromocriptine Therapy 
Drawbacks associated with the use of bromocriptine include high rates of nausea, 
considerable cost as well as inadequate information with regards to the efficacy and safety of 
bromocriptine (Nasser, 2011; Garber et al., 2013). 
 
2.10. Medicinal plants and diabetes mellitus-linked male reproductive dysfunction 
Herbal medicine is the oldest and most popular form of healthcare practice known to 
humanity and has been practiced by all cultures in all ages throughout the history of 
civilisation (Chikezie et al., 2015). Because medicinal plants are more compartible with the 
human body, their usage is usually associated with lesser side effects and are culturally 
acceptable. As such, medicinal plants have remained the mainstay of more than 70% of the 
world population particulary in developing countries where a large population might not have 
access to basic conventional therapies (Acharya & Shrivastava, 2008; Sen et al., 2010).  
 
Before the introduction of synthetic antidiabetic drugs, diabetes was treated with medicinal 
plants (Piero et al., 2012); however, the use of medicinal plants for the treatment of diabetes 
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in developed countries declined during the early part of the 20th century following the 
introduction of conventional antidiabetic oral agents and insulin therapy. Recently however, 
there has been increased interest in the usage of medicinal plants because of the high cost, 
advese effects and secondary failure rates associated with pharmacological and diabetic 
agents (Gurib-Fakim, 2006; Yatoo et al., 2017).  
 
The use of plant-derived medicines is based on the premise that plants are a rich source of 
safer, well-tolerated substances that are relatively less expensive and globally competitive 
(Sen et al., 2010). Medicinal plants are viewed as an easily available, potent source of 
antioxidants capable of scavenging free radicals and fighting diabetes-induced oxidative 
stress and have proven to be clinically effective and relatively less toxic than existing 
antidiabetic orthodox drugs (Sen et al., 2010; Bhatt et al., 2013). Piero et al, (2012) 
acknowledged that medicinal plants have been used in the management of diabetic 
complications and results of several other studies support the idea that medicinal plants have 
significant beneficial effects towards the management of diabetes-induced fertility problems 
(Oliveira et al., 2015). As such, the use of medicinal plants can be a source of new hope in 
the management of diabetes-associated male infertility as an affordable treatment method 
with fewer side effects.  
 
2.11. Catharanthus roseus 
Catharanthus roseus (L.) G. Don (C. roseus) is an important medicinal plant that belongs to 
the family Apocynaecea (Vega-Vila et al., 2012). C. roseus has previously been known as 
Vinca Rosea and is commonly known as the Madagascar periwinkle since it is native to 
Madagascar (Tiong et al., 2013). This plant presents as an erected, procumbent, evergreen 
subshrub with white to dark pink flowers that grows to a height of 1 metre (Frode & Medeiros, 
2008; Gajalakshmi et al., 2013). The leaves of C. roseus are glossy and dark green in colour, 
oblong to elliptic in shape (Aslam et al., 2010), 1.0-3.5 cm broad, have a pale midrib and a 
short petiole of approximately 1.0 – 1.8 cm in length arranged in opposite pairs (Gajalakshmi 
et al., 2013). C. roseus blooms throughout the year and is propagated by seedlings or 
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cuttings (Aslam et al., 2010). Flowers of C. roseus have 5 petals that range from white to 
dark-pink in colour with a darker red centre (Gajalakshmi et al., 2013).  Figure 2.4 shows the 
plant presentation of Catharanthus roseus. On the basis of floral colour, C. roseus has been 
classified into 2 classes namely the pink- flowered ‘Rosea’ and white-flowered ‘Alba.’ (Jaleel 
& Panneerselvam, 2007). Besides the 2 classifications for C. roseus, horticulturists have 
developed more than 100 different varieties of C. roseus with colours ranging from white to 
pink to purple (Aslam et al., 2010).  
 
Although C. roseus originates from Madagascar, it is now distributed around the world due to 
its ability to survive in a variety of habitats and its use as an ornamental plant (Van Bergen & 
Snoeijer, 1996). C. roseus has been cultivated in countries such as South Africa, India 
(Akhtar et al., 2007), China, Mexico (Patel et al., 2012) and Malaysia (Ong et al., 2011) 
where it has been utilised as a medicinal plant in the treatment of various ailments (Li et al., 
2004; Aslam et al., 2010).  
 
Figure 2.4: Catharanthus roseus plant presentation (Robertson, 2008) 
Traditionally, C. roseus has been used to relieve muscle pain, CNS depression, wasp stings, 
manage nose bleeding, mouth sores, sore throats and bleeding gums as well as in the 
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treatment of memory loss, hypertension, gastritis, cystitis, diarrhoea and hyperglycaemia 
(Dessisa, 2001). In Southern and Central America, C. roseus was used as a homemade 
remedy for easing lung congestion and inflammation while the flower extracts were useful in 
the treatment of eye irritations and infections by inhabitants of the Caribbean (Aslam et al., 
2010).  
 
C. roseus has been extensively investigated from ancient times for its pharmacological 
effects and phytochemical components (Gajalakshmi et al., 2013). Scientific research has 
confirmed C. roseus as a medicinal plant with antihelminthic activity, antitumour activity, 
antimutagenic activity, antihypertensive activity, antifungal activity, antimitotic activity, 
antinflammatory activity, antihypercholesterolemic activity, antidiuretic activity, cardiotonic 
activity, CNS depressant activity, antimalarial activity, antibacterial activity ,antiviral activity 
as well as antidiabetic activities (Aslam et al.,2010; Gajalakshmi et al., 2013) and qualitative 
analysis of phytochemical constituents of aqueous and ethanolic extracts of C. roseus have 
revealed the presence of alkaloids, tannins, flavonoids, terpenoids, glycosides, phenols, 
steroids, saponins, antioxidants and many other secondary metabolites (Patharajan & 
Abirami, 2014).  
 
2.12. Antidiabetic and antioxidant activities of C. roseus 
C. roseus has been traditionally used in the management of diabetes in various settings as it 
was believed to promote the production of insulin and increase the usage of sugars derived 
from food in cases of diabetes (Singh et al., 2001). Extensive research has been conducted 
to determine the efficacy of C. roseus as an antidiabetic and antioxidant agent and results 
have demonstrated that C. roseus has excellent antidiabetic and antioxidant properties 
(Rasineni et al., 2010; Vega-vila et al., 2012; Patharajan & Abirami, 2014; Al-Shaqha et al., 
2015; Nisar et al., 2017). The antidiabetic and antioxidant activities of C. roseus can be 
attributed to the presence of a variety of hypoglycaemic phytochemical constituents as well 
as free- radical scavengers and antioxidants within this plant’s extracts (Singh et al., 2014). 
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2.13. Vindoline  
C. roseus produces more than 130 different alkaloids, some of which exhibit strong and 
important pharmacological properties making it an economically valuable medicinal plant 
(Vega-Vila et al., 2012; Almagro et al., 2015). Amongst the many alkaloids derived from C. 
roseus is vindoline (C25H32N2O6; Molecular Weight 456.539 grams/mole); which is an 
intermediate, semi-synthetic monomeric vinca alkaloid that is used as a precursor to 
vincristine and vinblastine; drugs currently in use for their antineoplastic properties (Verma et 
al., 2007; Zhu et al., 2015). Figure 2.5 outlines the chemical structure of vindoline. 
 
Figure 2.5: Chemical Structure of vindoline (Merck, 2018)  
Vindoline can be extracted from the aerial parts of C. roseus and is primarily used in the 
treatment of cancer because of its ability to repress cell growth by altering microtubular 
dynamics thereby provoking apoptosis (Nirmala et al., 2011; Chandrasekaran et al., 2014). 
Besides the antimitotic effects of vindoline, research has demonstrated the possible efficacy 
of vindoline in the treatment of diabetes mellitus. Vindoline has been reported to exhibit 
antidiabetic properties in diabetes-induced animal models by increasing glucose-stimulated 
insulin release, lowering blood glucose levels, inhibiting Kv2.1 potassium channels, 
decreasing the K+ outward current, lowering glycated haemoglobin, reducing triglyceride 
levels and inhibiting H+/K+ ATPases (Sertel et al., 2011; Tiong et al., 2013; Yao et al., 2013).  
 
Diabetes-induced male reproductive dysfunction is a consequence of oxidative stress 
produced in diabetic conditions. Because of the revealed antidiabetic and antioxidant 
properties of vindoline, it is therefore envisaged that this alkaloid could be useful in the 
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management of diabetes-induced male infertility. This research therefore sought to assess 
the antioxidant and antidiabetic activities of vindoline on testicular and epididymal tissues in 
STZ-induced diabetic and non-diabetic rats. 
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CHAPTER THREE 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1. Type of study 
This research was a laboratory-based experimental study. 
 
3.2. Animal Requirements 
Forty-eight, 6 week old, male Wistar rats, Rattus Norvegicus, 190-230g body mass, with a 
conventional microbial status were obtained from the Primate Unit and Delft Animal care, 
South African Medical Research Council, and used for this study. 
 
3.3. Place of study 
Animal feeding and sacrifice was done at the South African Medical Research Council in 
Parrow, Western Cape, South Africa; while laboratory analysis of samples obtained from the 
rats was carried out at the Oxidative Stress Research Centre of the Cape Peninsula  
University of Technology, Bellville; South Africa. 
 
3.4. Ethical Consideration 
Ethical approval was sought and obtained from the Research Ethics Committee, (CPUT/HW-
REC 2017/A1), Faculty of Health and Wellness Sciences, Cape Peninsula University of 
Technology. All animals received humane care and were treated with respect according to 
the principles of Laboratory Animal Care of the National Society of Medical Research and the 
National Institute of Health Guide for the Care and Use of Laboratory Animals of the National 
Academy of Sciences (National Institutes of Health, Publication Number 80-23, Revised 
1978).  
 
3.5. Source of vindoline 
Vindoline used for this study was commercially purchased from Best of Chemicals; United 
States of America. 
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3.6. Experimental Design 
The experiment comprised 6 groups of rats; each group with 8 rats. The first 3 groups 
(groups 1, 2 and 3) were normal, non-diabetic male Wistar rats while the last 3 groups 
(groups 4, 5 and 6) were type 2 diabetes-induced male Wistar rats.  
 
3.7. Induction of diabetes 
Induction of T2DM followed the modified method of Wilson and Islam (2012), Kumar et al, 
(2014) and Mohamed et al, (2016). Diabetic groups (Groups 4, 5 and 6) received distilled 
water and 10% fructose water for the first 2 weeks of the study. At the end of 2 weeks, the 
administration of 10% fructose water was terminated and the rats were fasted overnight prior 
to the administration of a single intraperitoneal injection of STZ solution (Sigma, United 
States of America) at 40 mg/kg b.w. dissolved in sodium citrate at pH 4.4. Three days after 
STZ injection, drops of blood were collected from the tails and blood glucose levels were 
measured using a portable glucometer (Accu-Chek, Roche, Germany). Diabetes status was 
confirmed where glucose levels were above 18 mmol/l. 
 
3.8. Animal feeding 
All rats were fed with standard rat chow (SRC) purchased from AQUANUTRO Company 
(Mamelsbury, South Africa).  
 
Table 3.1: Composition of rat diets 
Nutrient Amount g/kg 
Protein 160       Minimum 
Moisture 120  Maximum 
Lipids 25  Minimum 
Fibre 60   Maximum 
Phosphorus 7   Minimum 
Calcium 18   Maximum 
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3.9 Animal Treatment  
All animals received humane care according to the principles of Laboratory Animal Care of 
the National Society of Medical Research and the National Institutes of Health Guideline for 
the Care and Use of Laboratory Animals of the National Academy of Sciences (National 
Institutes of Health publication no. 80-23, revised 1978). They were accommodated 
individually in plastic cages at the animal facility of the South African Medical Research 
Council and supplied with SRC and distilled water ad libitum. They were subjected to 
standard laboratory conditions of 22 ± 2°C and 12 hour light/dark cycles at humidity levels of 
55 ± 5%.  
 
Rats from the 6 different groups were subjected to different treatments as follows: 
 Group 1 comprised normal non-diabetic rats (n=8) and was considered the normal 
control. Rats from this group were treated with the vehicle, castor oil; 5 times a week 
for 5 weeks, fed on SRC and had access to distilled water ad libitum. 
 Group 2 comprised normal, non-diabetic rats (n=8), treated with vindoline                  
(20 mg/kg/b.w), 5 times a week for 5 weeks, using castor oil as the vehicle for the 
administration of vindoline. The rats were fed on SRC and had access to distilled 
water ad libitum 
 Group 3 comprised normal, non- diabetic rats (n=8) treated with glibenclamide        
(50 mg/kg/b.w), 5 times a week for 5 weeks. Glibenclamide is the standard drug for 
the treatment of diabetes. This group of rats was fed on SRC and allowed access to 
distilled water ad libitum.  
 Group 4 comprised untreated-diabetic rats (n=8) and was considered the diabetic 
control. Rats from this group were treated with the vehicle, castor oil, fed on SRC and 
allowed free access to distilled water ad libitum.  
 Group 5 was the diabetic group of rats (n=8), treated with vindoline (20 mg/kg/b.w.), 
using castor oil as the vehicle for administration. This group of rats was fed on SRC 
and allowed free access to distilled water ad libitum. 
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 Group 6 was the diabetic group of rats (n=8), treated with glibenclamide                  
(50 mg/kg/b.w.), 5 times a week for 5 weeks. Rats from this group were fed on SRC 
and allowed access to distilled water ad libitum. 
 
3.10. Sample collection and preparation 
Body weights were measured from the onset of the study and monitored throughout the 
feeding period until sacrifice. 72 hours after STZ injection, drops of blood were collected from 
the tails and blood glucose levels were measured using a portable glucometer (Accu-Chek, 
Roche, Germany). Diabetes status was confirmed where glucose levels were above            
18 mmol/l. On completion of the treatment periods, rats were fasted overnight in preparation 
for sacrifice and sample collection. Fasting blood glucose levels were measured after 4 hours 
of fasting. Rats were anaesthetised and euthanized using isoflurane gas at 2% with 1% 
oxygen during laparotomy. Following complete anaesthesia, blood was collected from the 
abdominal vena cava using 5ml syringes connected to a 23 gauge hypodermic needle and 
collected into appropriate tubes containing sodium fluoride/potassium oxalate. The 
epididymis and testes were excised, weighed and used for this research project. Testicular 
and epididymal tissue samples were snap-frozen in liquid nitrogen and stored at -80°C until 
ready for biochemical analysis. 
 
3.11. Biochemical Experiments 
All laboratory investigations were carried out at the Oxidative Stress Research Laboratory of 
the Cape Peninsula University of Technology, in Bellville; Western Cape Province of South 
Africa. 
 
3.12. Buffer solutions 
Fresh 50mM sodium phosphate buffer with 0.5% v/v Triton X-100 at pH 7.5 was used for 
homogenising all tissue samples. Thereafter, 50mM sodium phosphate buffer without Triton 
X-100 at pH 7.5 was used for diluting samples for purposes of running all the biochemical 
analyses.  
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3.13. Preparation of testicular and epididymal homogenates 
Using a balance, 100 mg of each tissue (testicular/ epididymal) was weighed and added to 
1ml of the 50Mm sodium phosphate buffer with Triton X-100 (pH 7.5) in a glass homogeniser 
on ice water. The tissues were homogenised in potter-elvehjam for five strokes on ice water 
and the homogenates were transferred to new tubes and sonicated on ice. The 
homogenates were centrifuged for 15 minutes at 15 000rpm at a temperature of 40C. The 
supernatant was transferred to newly marked tubes and stored at -800C until needed for 
protein determination and biochemical assays. 
   
3.14. Total Protein Determination Assay  
The Bicinchoninic Acid (BCA) protein assay is a detergent compatible formulation that is 
based on BCA for the colorimetric detection and quantitation of total protein concentration. It 
is a combination of the biuret reaction (characterised by the reduction of Cu2+ to Cu+ by 
protein in an alkaline medium) and the colorimetric detection of the produced Cu+ using a 
unique reagent containing BCA. The chelation of two molecules of BCA with a single Cu+ ion 
results in a water-soluble purple-coloured complex with a strong absorption at 562nm.  
  
3.14.1. Total Protein Determination Assay Methodology 
Total protein was quantified in accordance to the manufacturer’s instruction assay kit 
supplied by Sigma Aldrich. The BCA working reagent was prepared by mixing 50 parts of 
BCA Reagent A with 1 part of BCA reagent B [(50:1) Reagent A: Reagent B]. 100ml of 
Reagent A was therefore mixed with 2ml of Reagent B. Protein standards were prepared by 
serial dilutions of the BSA standard protein as outlined in the table below. 
Table 3.2: Serial dilutions of the BSA standard 
Standard (Std) Buffer BSA Final BSA 
Concentration 
Standard 5 325ʮl 325 ʮl 1000ʮg/ml 
Standard 4 325ʮl 325ʮl of Std 5 500ʮg/ml 
Standard 3 325ʮl 325ʮl of Std 4 250ʮg/ml 
Standard 2 325ʮl 325ʮl of Std 3 125ʮg/ml 
Standard 1 400ʮl 100ʮl of Std 2 25ʮg/ml 
Blank 400ʮl 0 0 
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Using a 96-well plate, 25ʮl of the blank, each standard and unknown testicular and 
epididymal samples were pipetted into each well in triplicates. 200ʮl of the BCA working 
reagent was added into each well using a multiple channel pipette. The contents of each well 
were thoroughly mixed on a plate shaker for 30 seconds and the microplate was allowed to 
cool at room temperature. Absorbance was then measured at 562nm on a microplate reader 
(Thermo Electron Corporation, Multiskan spectrum, United States of America).  
 
The BCA assay has a broad working range of 20- 2000ʮg/ml, and protein concentration of 
the unknown samples were determined and reported with reference to standards of a 
common protein. In this assay; Bovine Serum Albumin (BSA) was used as the common 
protein. A series of BSA dilutions were prepared and assayed alongside the unknowns. 
Protein concentrations of the unknowns were quantified using the standard curve generated 
from BSA and results were expressed as ʮg/ml. 
 
3.15. TBARS ASSAY 
Malondialdehyde (MDA), a meta-stable end-product of lipid peroxidation (LPO) can be 
assayed through the thiobarbituric acid reactive substances (TBARS) Assay which is a 
simple and useful diagnostic tool for the measurement of LPO for in-vitro and in-vivo 
systems. The TBARS assay involves the reaction of MDA at 900C under acidic conditions to 
produce a pink-coloured chromogen that strongly absorbs at a wavelength of 532nm. 
 
3.15.1. TBARS Assay Methodology 
Briefly, 100ʮl of each testicular/epididymal homogenate was mixed with 12.5ʮl of butylated 
hydroxytoluene (BHT) ethanol and 100ʮl of 0.2M O-PA in a 2ml eppindoff tube. 12ʮl of 
thiobarbituric acid in 0.1M NaOH was added to the same mixture and the tubes were 
vortexed and incubated in a 900C water-bath for 45 minutes. The tubes were then cooled on 
ice water. 1000ʮl of butanol and 100ʮl of NaCI were added into each tube and the tubes 
were vortexed. Using a 96-well plate, 300ʮl of butanol/each prepared testicular and 
epididymal samples were pipetted into each well in triplicates and the absorbance of the 
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pink-coloured chromogen was measured spectrophotometrically at 532nm on a microplate 
reader (Thermo Electron Corporation, Multiskan spectrum, United States of America). 
Results were expressed in ʮmol/g. 
 
3.16. SOD ASSAY  
The following SOD activity assay is a modification of the methodology outlined by Ellerby and 
Bredesen, 2000. SOD is one of the most important antioxidant enzymes that catalyses the 
dismutation of the superoxide radical into the less destructive H2O2 and molecular oxygen. 
The SOD assay uses 6 hydroxydopamine (6-HD, Sigma Cat H8523) and 
diethylenetriaminepentaacetic acid (DETAPAC, Sigma Cat CD6518) to generate superoxide 
anions. However, in the presence of SOD, the superoxide anion concentrations are reduced, 
yielding less colorimetric signal. The kinetics of the autoxidation of 6-HD is monitored at 
490nm at 250C for ± 4 minutes. 
 
3.16.1. SOD Assay Methodology 
In a 15ml tube, 1.6mM 6-HD was freshly prepared by mixing 10ml of distilled water and 50ʮl 
of perchloric acid for 15 minutes. 10 ml of this solution was measured, and to this, 4mg of 6-
HD was added. The tube was labelled as 6-HD, stored on ice and used as soon as possible. 
0.1mM DETAPAC solution was prepared by dissolving 2mg of DETAPAC in 50 ml of the 
50mM sodium phosphate buffer without Triton X-100 and mixing the solution. This solution 
was stored at -200C and used as soon as possible. Tubes were labelled and into each tube, 
50ʮl of the 50mM sodium phosphate buffer and 50ʮl of the blank/ testicular/ epididymal 
homogenates were added making up a 2× dilution of the samples’ original concentrations. 
Using a 96-well plate; 12ʮl of the blank/diluted testicular and epididymal samples was added 
into each respective well in triplicates. Using a multiple-channel pipette, 15ʮl of the 6-HD 
solution and 170ʮl of the DETAPAC solution was added into each well making a total volume 
of 197ʮl for each well. The absorbance was measured immediately at 490nm for 4min at 
1min intervals on a microplate reader (Thermo Electron Corporation, Multiskan spectrum, 
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United States of America). The activity of SOD was calculated from a linear calibration curve 
and expressed as µmol/mg protein. 
 
3.17. CATALASE ASSAY  
Catalase activity was determined by measuring the amount of substrate (H2O2) remaining 
after sample addition (Aebi, 1984). This assay is based on the enzymatic detoxification of 
H2O2 by catalase into molecular oxygen and water molecules. The rate of H2O2 disintegration 
into water molecules and molecular oxygen is proportional to the concentration of catalase in 
the sample. The catalase-containing sample is incubated with a known amount of H2O2 and 
the rate of H2O2 disintegration is proportional to the concentration of catalase present in the 
sample. 
 
3.17.1. Catalase Assay Methodology 
Determination of Catalase activity followed the methodology outlined by Ellerby and 
Bredesen, (2000). H2O2 solution was prepared by adding 34ʮl of the H2O2 stock solution to 
10ml of the 50mM sodium phosphate buffer at pH 7.5. Testicular and epididymal tissue 
homogenates were diluted 5× by adding 10ʮl of each homogenate to 40ʮl of the 50mM 
sodium phosphate buffer. Using a 96 well plate, 10ʮl of the blank and each diluted unknown 
tissue sample were pipetted into each well in triplicates. 170ʮl of the 50mM sodium 
phosphate buffer was added to each well using a multiple channel pipette. The loaded 96 
well plate was carried to the spectrophotometer where 75ʮl of the H2O2 solution was added 
to each well using a multiple channel pipette. The plate was immediately loaded onto the 
microplate reader (Thermo Electron Corporation, Multiskan spectrum, United States of 
America) and absorbance was measured at 240nm. Catalase activity results were expressed 
as ʮmol/mg of protein. 
 
3.18. FRAP ASSAY 
The Ferric Reducing Antioxidant Power (FRAP) assay is used to rank the reducing power 
and antioxidant potential of a wide range of biological samples. It is an endpoint assay that 
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uses antioxidants as reducing agents in a redox-linked colorimetric method employing an 
easily reduced oxidant, Fe3+. The reduction of colourless Fe3+ to blue Fe2+ can be monitored 
spectrophotometrically at 593nm where absorbance readings are related to the reducing 
power of the electron-donating antioxidants present in the sample. 
 
3.18.1. FRAP Assay Methodology 
This FRAP assay methodology is a modification of the methodology outlined by Benzi and 
Strain, (1996). Iron chloride solution (FeCl3) was prepared by dissolving 0.053g of FeCl3 in 
10ml of distilled water. TPTZ solution was prepared by dissolving 0.0279g of TPTZ in 9ml of 
0.1M hydrochloric acid. The FRAP reagent was prepared by adding 90ml of the 50mM 
sodium phosphate buffer solution (pH 7.5) with 9ml of the already prepared FeCl3 solution, 
9ml of the TPTZ solution and 18ml of distilled water. Ascorbic acid (AA) was diluted into 
different standard solutions as shown on the table below. 
 
Table 3.3: Preparation of FRAP standards 
Standard Ascorbic Acid Distilled 
Water  
Blank 0 1000 
Standard 1 50ʮl 950ʮl 
Standard 2 100ʮl 900ʮl 
Standard 3 250ʮl  750ʮl 
Standard 4 500ʮl 500ʮl 
Standard 5 1000ʮl 0 
 
Using a 96-well microplate; 10ʮl of the blank, each standard and respective testicular and 
epididymal samples were pipetted into each well in triplicates. 300ʮl of the FRAP working 
reagent was added into each well using a multiple channel pipette and the plate was 
incubated for 30 minutes at 370C. The plate was then loaded into the spectrophotometer 
(Thermo Electron Corporation, Multiskan spectrum, United States of America) where 
absorbance was measured at 593nm. Results were compared to a standard curve and 
expressed in μmol/g.  
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3.19. ORAC ASSAY 
Oxygen Radical Absorbance Capacity (ORAC) is a kinetic assay that measures fluorescein 
and antioxidant decay over time in biological fluids, cells and tissue samples. The ORAC 
assay provides a comprehensive analysis of test sample antioxidant activity by measuring 
hydrogen atom transfer. It measures loss of fluorescein florescence over time due to peroxyl 
radical formation during the time-dependant, thermal decomposition of AAPH (2,2- azobis-2-
methyl-propanimidamide, dihydrochloride) at 370C. The peroxyl radicals can oxidise 
fluorescein to generate a product without fluorescence. Antioxidants however suppress this 
reaction by hydrogen atom transfer thereby inhibiting the oxidative degradation of the 
fluorescein signal.  
 
In this assay, Trolox (6-hydroxy-2, 5, 7, 8- tetramethylchroman-2 carboxylic acid), a water 
soluble Vitamin E analog, served as a positive control by inhibiting fluorescein decay in a 
dose-dependent manner. The concentration of the antioxidant in the unknown sample was 
proportional to the intensity of the fluorescence generated throughout the course of the assay 
and the dynamics of the signal inhibition were expressed as the area under the curve 
generated by Trolox. 
  
3.19.1. ORAC Assay Methodology 
The following ORAC methodology is a modification of the methodology by Rautenbach and 
co-workers, (2010). Testicular and epididymal samples were deproteinated by mixing 50ʮl of 
each homogenised tissue with 50ʮl of perchloric acid making a 2× dilution of the original 
sample concentration. The mixture was vortexed and centrifuged at 14 000rpm for 1minute 
at 40C. 50ʮl of each supernatant was then added to 200ʮl of the 75mM ORAC buffer 
solution at pH 7.5 making an additional 5× dilution of the tissue samples. Fluorescein was 
prepared by adding 10ʮl of fluorescein to 2ml of the ORAC buffer in a 2.5ml tube. 300ʮl of 
this mixed solution (10ʮl fluorescein + 2ml ORAC buffer) was then pipetted into a 15ml tube 
and 15ml of the ORAC buffer solution was added into that tube. AAPH was prepared by 
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adding 0.150g of AAPH to 6ml of the 75Mm ORAC buffer in a 15ml tube. Standard Trolox 
was diluted as shown in the table below. 
Table 3.4: Preparation of ORAC standards 
Standard Buffer  Trolox 
Blank 750ʮl 0 
Standard 1 625ʮl 125ʮl 
Standard 2 500ʮl 250ʮl 
Standard 3 325ʮl  325ʮl 
Standard 4 250ʮl 500ʮl 
Standard 5 125ʮl 625ʮl 
 
 
Using a 96-well plate, 12ʮl of the blank, each standard and deproteinated testicular and 
epididymal homogenates were added into each well in triplicates. Using a multiple channel 
pipette, 138ʮl of fluorescein was added into each well. The loaded 96-well plate was carried 
to the reading machine where 50ʮl of the AAPH solution was added into each well using a 
multiple-channel pipette. The 96-well plate was then loaded into the machine where results 
were generated over a period of 2 hours. The regression equation (Y=a+bX+cX2) was used 
to determine ORAC values where Y= Trolox concentration in μM and X= net area under the 
fluorescence decay curve. Results were reported in Trolox equivalents per millilitre/μmol. The 
area under the curve (AUC) was calculated as follows: 
AUC= (0.5 +f2 / f1 +f3 / f1 +f4 / f1 +………+ fi / f1) × CT. 
Where f1 is the initial reading at cycle 1, fi is the reading at cycle I and CT is the cycle time in 
minutes. 
 
3.20. Statistical analysis  
Data was expressed as mean ± standard error of the mean (Mean ± SEM). One-way 
analysis of variance (ANOVA) was used to test for significance between the different 
experimental groups. The Bonferroni Multiple Comparison analysis was used to compare the 
differences between multiple groups. Statistical analysis of two groups was performed using 
the unpaired student’s t-test. Differences were considered significant at p<0.05. GraphPad 
PRISM 5 software package and Microsoft Excel 2010 were used for all statistical evaluations 
and graphical representations. 
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CHAPTER FOUR 
RESULTS 
 
4.1. Initial blood glucose levels in diabetic and non-diabetic groups before treatments. 
Diabetes was induced by subjecting rats to be used as group 4, 5 and 6 subjects to 10% 
fructose water for 2 weeks and thereafter administering a single intraperitoneal injection of 
40mg/kg b.w of STZ. Fasting blood glucose levels of diabetes-induced male Wistar rats were 
measured 72 hours after STZ injection. Initial fasting blood glucose levels of normal, non-
diabetic rats (used as group 1, 2 and 3 subjects) and diabetic rats (used as group 4, 5 and 6 
subjects) are presented in Figure 4.1. The average fasting blood glucose levels of diabetic 
rats was significantly higher in comparison to fasting blood glucose levels of normal, non-
diabetic rats (29.27 ± 0.7882 mmol/l versus 11.21 ± 0.9771 mmol/l), p<0.05.    
 
G
lu
co
se
 (m
m
ol
/l)
Normal Diabetic
0
10
20
30
40
b
   
Figure 4.1: Fasting blood glucose levels of normal, non-diabetic rats and diabetic male Wistar 
rats before subjection to various treatments. Data is presented as mean ± SEM. (b) indicates a 
significant difference of normal fasting blood glucose levels when compared to the diabetic group, 
p<0.05, mmol/l: millimoles per litre. 
 
4.2. Evaluation of blood glucose levels after subjecting rats to various treatments. 
Figure 4.2 shows fasting blood glucose levels of non-diabetic and diabetic rats after being 
subjected to various treatments for 5 weeks. The difference in fasting blood glucose levels 
between the normal control (group 1) and non-diabetic rats treated with vindoline (group 2) 
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(10.56 ± 0.3380 mmol/l versus 10.03 ± 0.9161 mmol/l) and the difference between fasting 
blood glucose levels of group 1 and group 3 (non-diabetic rats treated with glibenclamide) 
(10.56 ± 0.3380 mmol/l versus 10.18 ± 0.2944 mmol/l) was not statistically significant 
(p>0.05). The difference in final fasting blood glucose levels between groups 2 and 3 (10.03 
± 0.9161 mmol/l versus 10.18 ± 0.2944 mmol/l) was also non-significant, p>0.05. The 
average fasting blood glucose level of the diabetic control (group 4) was significantly higher 
in comparison to fasting blood glucose levels of the normal control (group 1), (31.94 ± 0.5438 
mmol/l versus 10.56 ± 0.3380 mmol/l), p<0.05. Diabetic rats treated with vindoline (group 5) 
and diabetic rats treated with glibenclamide (group 6) had significantly higher fasting blood 
glucose levels (p<0.05 when compared to the normal control (group 1), (27.15 ± 1.472 
mmol/l versus 10.56 ± 0.3380 mmol/l) and (29.23 ± 1.335 mmol/l versus 10.56 ± 0.3380 
mmol/I) respectively). An insignificant difference (p>0.05), wasnoted between the final fasting 
blood glucose levels of the diabetic control (group 4) and diabetic rats treated with 
glibenclamide (group 6), (31.94 ± 0.5438 mmol/l versus 29.23 ± 1.335 mmol/l). The average 
fasting blood glucose levels of diabetic rats treated with vindoline (group 5), were however 
significantly lower in comparison to that of the diabetic control (group 4), (27.15 ± 1.472 
mmol/l versus 31.94 ± 0.5438 mmol/l). There was no significant difference between final 
fasting blood glucose levels of group 5 and group 6 after 5 weeks of subjection to different 
treatments (27.15 ± 1.472 mmol/l versus 29.23 ± 1.335 mmol/l). 
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide  
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Figure 4.2: Fasting blood glucose levels of various groups after subjection to various 
treatments. Data is presented as mean ± SEM. (d) indicates significant difference of groups when 
compared to group 4 at p<0.05; (e) indicates significant difference of groups when compared to group 
5 at p<0.05 and (f) indicates significant difference of groups when compared to group 6 at p<0.05, 
mmol/l;  millimoles per litre. 
 
4.3. Evaluation of body weights after subjecting rats to treatments.  
Figure 4.3 shows final body weight measurements of non-diabetic and diabetic male Wistar 
rats after being subjected to various treatments for 5 weeks. The mean final body weight of 
non-diabetic rats treated with vindoline (group 2) was significantly higher in comparison to 
that of the normal control (group 1), (338.4 ±13.10g versus 293.0 ± 8.251g). There was no 
significant difference between final body weights of the non-diabetic control (group 1) and 
non-diabetic rats treated with glibenclamide (group 3), (293.0 ± 8.251g versus 310.0 ± 
10.41g). Additionally, the difference in final body weights between groups 2 and 3 was not 
significant (338.4 ±13.10g versus 310.0 ± 10.41g), p>0.05. Final body weights of the diabetic 
control (group 4), were significantly lower in comparison to those of the normal control (group 
1), (243.1 ± 11.88g versus 293.0 ± 8.251g), p<0.05. The final body weights of non-diabetic 
rats treated with vindoline (group 2) were significantly higher (p<0.05) in comparison to mean 
final body weights of the following diabetic groups; group 4 (338.4 ± 13.10g versus 243.1 ± 
11.88g), group 5 (338.4 ± 13.10g versus 241.0 ± 9.417g) and group 6 (338.4 ± 13.10g versus 
255.0 ± 5.586g). The difference in final body weights between the diabetic control (group 4) 
and diabetic rats treated with vindoline (group 5); (243.1 ± 11.88g versus 241.0 ± 9.417g) 
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and the difference between final body weights of the diabetic control (group 4) and diabetic 
rats supplemented with glibenclamide (group 6); (243.1 ± 11.88g versus 255.0 ± 5.586g)  
was not statistically significant, (p>0.05). There was no significant difference in final body 
weights between groups 5 and 6 (241.0 ± 9.417g versus 255.0 ± 5.586g), p>0.05. 
  
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide   
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Figure 4.3: Final body weights of various groups after subjection to various treatments. Data is 
presented as mean ± SEM. (b) indicates significant difference of groups when compared to group 2 at 
p<0.05, (d) indicates significant difference of groups when compared to group 4 at p<0.05; (e) 
indicates significant difference of groups when compared to group 5 at p<0.05 and (f) indicates 
significant difference of groups when compared to group 6 at p<0.05. 
 
4.4. Effect of vindoline on testicular and epididymal weights  
Figure 4.4 compares testicular weights of type 2 diabetes-induced rats and non-diabetic rats 
after 5 weeks of subjection to various treatments. The differences in testicular weights 
between the normal control (group 1) and non-diabetic rats treated with vindoline (group 2), 
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(2.647 ± 0.09365g versus 2.941 ± 0.06671g) and the difference between testicular weights of 
the normal control (group 1) and non-diabetic rats treated with glibenclamide (group 3), 
(2.647 ± 0.09365g versus 2.906 ± 0.08967g) were not significantly different, p>0.05. There 
was no significant difference between testicular weights of groups 2 and 3 (2.941 ± 0.06671g 
versus 2.906 ± 0.08967g), p>0.05. The average testicular weight of the diabetic control 
(group 4) was significantly lower in comparison to that of the normal control (group 1), (2.123 
± 0.04656g versus 2.647 ± 0.09365g), p<0.05. Diabetic rats treated with vindoline (group 5) 
and diabetic rats treated with glibenclamide (group 6) had significantly lower testicular 
weights (p<0.05), in comparison to testicular weights of the normal control (group 1); (2.299 ± 
0.06905g versus 2.647 ± 0.09365g) and (2.275 ± 0.06370g versus 2.647 ± 0.09365g), 
respectively. There was no significant difference (p>0.05), between testicular weights of 
group 4 and group 5 (2.123 ± 0.04656g versus 2.299 ± 0.06905g). Testicular weights of 
diabetic rats treated with glibenclamide (group 6) were not significantly different in 
comparison to testicular weights of group 4, (2.275 ± 0.06370g versus 2.123 ± 0.04656g). 
The difference in testicular weights between group 5 and group 6 was not statistically 
significant (2.299 ± 0.06905g versus 2.275 ± 0.06370g), p>0.05.  
 
Figure 4.5 compares epididymal weights of diabetes-induced rats and non-diabetic rats after 
being subjected to various treatments for 5 weeks. The difference in epididymal weights 
between the normal control (group 1) and non-diabetic rats treated with vindoline (group 2) 
was non-significant, (1.047 ± 0.02988g versus 1.050 ± 0.02712g), p>0.05. Epididymal 
weights of non-diabetic rats treated with glibenclamide (group 3) were not statistically 
different in comparison to those of the normal control (group 1), (1.066 ± 0.01710g versus 
1.047 ± 0.02988g), p>0.05. The difference between epididymal weights of groups 2 and 3 
was statistically insignificant, (1.050 ± 0.02712g versus 1.066 ± 0.01710g), p>0.05. The 
differences between epididymal weights of the diabetic control (group 4) and diabetic rats 
treated with vindoline (group 5), (0.9202 ± 0.007020g versus 0.9720 ± 0.004497g) and the 
difference between epididymal weights of the diabetic control (group 4) and diabetic rats 
treated with glibenclamide (group 6), (0.9202 ± 0.007020g versus 0.9562 ± 0.005837g) were 
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not significant, p>0.05. Epididymal weights of group 5 and group 6 were not statistically 
different (0.9720 ± 0.004497g versus 0.9562 ± 0.005837g), p>0.05. Epididymal weights of 
non-diabetic groups (group 1, group 2 and group 3) were significantly higher than epididymal 
weights of the diabetic control (group 4); (1.047 ± 0.02988g versus 0.9202 ± 0.007020g), 
(1.050 ± 0.02712g versus 0.9202 ± 0.007020g) and (1.066 ± 0.01710g versus 0.9202 ± 
0.007020g), respectively. 
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide   
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Figure 4.4: Testicular weights of various groups after subjection to various treatments. Data is 
presented as mean ± SEM. (d) indicates significant difference of groups when compared to group 4 at 
p<0.05; (e) indicates significant difference of groups when compared to group 5 at p<0.05 and (f) 
indicates significant difference of groups when compared to group 6 at p<0.05. 
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Figure 4.5: Epididymal weights of various groups after subjection to various treatments. Data is 
presented as mean ± SEM. (d) indicates significant difference of groups when compared to group 4 at 
p<0.05 and (f) indicates significant difference of groups when compared to group 6 at p<0.05. 
 
4.5. Effects of vindoline on testicular and epididymal lipid peroxidation levels  
Figure 4.6 demonstrates a non-significant difference (p>0.05), between testicular MDA levels 
of the normal control (group 1) and non-diabetic rats treated with vindoline (group 2), (0.2847 
± 0.01239 ʮmol/g versus 0.2770 ± 0.02008 ʮmol/g). The difference between testicular MDA 
levels of the normal control (group 1) and testicular MDA levels of non-diabetic rats treated 
with glibenclamide (group 3), was statistically insignificant (0.2847 ± 0.01239 ʮmol/g versus 
0.2905 ± 0.001540 ʮmol/g), p>0.05. There was no significant difference between testicular 
MDA levels of groups 2 and 3 (0.2770 ± 0.02008 ʮmol/g versus 0.2905 ± 0.001540 ʮmol/g), 
p>0.05. Testicular MDA levels of the diabetic control (group 4) were significantly higher in 
comparison to testicular MDA levels of the normal control (group 1), (0.3890 ± 0.01046 
ʮmol/g versus 0.2847 ± 0.01239 ʮmol/g), p<0.05. Diabetic rats treated with vindoline (group 
5) and diabetic rats treated with glibenclamide (group 6) had significantly lower testicular 
MDA levels in comparison to testicular MDA levels of the diabetic control (group 4); (0.2654 ± 
0.02747 ʮmol/g versus 0.3890 ± 0.01046 ʮmol/g) and (0.2877 ± 0.01934 ʮmol/g versus 
0.3890 ± 0.01046 ʮmol/g) respectively. The difference in testicular MDA levels between 
groups 5 and 6 (0.2654 ± 0.02747 ʮmol/g versus 0.2877 ± 0.01934 ʮmol/g) was statistically 
insignificant (p>0.05). 
 59
Figure 4.7 demonstrates the effect of various treatments on epididymal MDA levels in adult 
male Wistar rats. No significant difference (p>0.05) was observed between epididymal MDA 
levels of the normal control (group 1) and non-diabetic rats treated with vindoline (group 2) 
(0.1913 ± 0.2290 ʮmol/g versus 0.1410 ± 0.01164 ʮmol/g). Figure 4.7 also shows a non-
significant difference (p>0.05) between lipid peroxidation levels of the normal control (group 
1) and non-diabetic group of rats treated with glibenclamide (group 3), (0.1913 ± 0.2290 
ʮmol/g versus 0.2115 ± 0.01492 ʮmol/g). Epididymal MDA levels of the diabetic control 
(group 4) were significantly higher in comparison to those of the normal control (group 1), 
(0.4846 ± 0.03188 ʮmol/g versus 0.1913 ± 0.2290 ʮmol/g) p<0.05. No significant difference 
was observed between epididymal MDA levels of the diabetic control (group 4) and diabetic 
rats treated with vindoline (group 5), (0.4846 ± 0.03188 ʮmol/g versus 0.3756 ± 0.03689 
ʮmol/g), p>0.05. The difference between epididymal lipid peroxidation levels of the diabetic 
control (group 4) and diabetic rats treated with glibenclamide (group 6) was not significant 
(0.4846 ± 0.03188 ʮmol/g versus 0.4380 ± 0.04474 ʮmol/g). The difference between 
epididymal MDA levels of groups 5 and 6 (0.3756 ± 0.03689 ʮmol/g versus 0.0.4380 ± 
0.04474 ʮmol/g) was insignificant, p>0.05. Overall, epididymal MDA levels of non-diabetic 
groups (Groups 1, 2 and 3) were significantly lower in comparison to epididymal MDA levels 
of diabetic groups (Groups 4, 5 and 6). 
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide   
 60
Experimental Groups
Te
st
ic
ul
ar
 M
D
A 
Le
ve
ls
 ( 
m
ol
/g
)
1 2 3 4 5 6
0.0
0.1
0.2
0.3
0.4
0.5
d d d
ef
 
Figure 4.6: Testicular MDA levels of various groups after subjection to various treatments. Data 
is presented as mean ± SEM. (d) indicates significant difference of groups when compared to group 4 
at p<0.05, (e) indicates significant difference of groups when compared to group 5 at p<0.05 and (f) 
indicates significant difference of groups when compared to group 6 at p<0.05, ʮmol/g: micromoles 
per gram. 
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Figure 4.7: Epididymal MDA levels of various groups after subjection to various treatments. 
Data is presented as mean ± SEM. (d) indicates significant difference of groups when compared to 
group 4 at p<0.05; (e) indicates significant difference of groups when compared to group 5 at p<0.05 
and (f) indicates significant difference of groups when compared to group 6 at p<0.05. ʮmol/g: 
micromoles per gram. 
 
4.6. Effects of vindoline on testicular and epididymal SOD activities 
Figure 4.8 compares testicular SOD activities between non-diabetic and diabetic rats after 5 
weeks of subjection to various treatments. The difference in testicular SOD activity between 
non-diabetic rats supplemented with vindoline (group 2) and the normal control (group 1) was 
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not significant (1.041 ± 0.03497 ʮmol/mg versus 1.063 ± 0.007962 ʮmol/mg), p>0.05. There 
was no significant difference between testicular SOD activities of the normal control (group 1) 
and non-diabetic rats treated with glibenclamide (group 3), (1.063 ± 0.007962 ʮmol/mg 
versus 0.9725 ± 0.0347 ʮmol/mg), p>0.05. The difference between testicular SOD activities 
of groups 2 and 3 (1.041 ± 0.03497 ʮmol/mg versus 0.9725 ± 0.0347 ʮmol/mg) was also 
insignificant, p>0.05. The average SOD activity in testicular tissues of the diabetic control 
(group 4) were significantly lower in comparison to that of the normal control (group 1) 
(0.8313 ± 0.3629 ʮmol/mg versus 1.063 ± 0.007962 ʮmol/mg), p<0.05. No significant 
difference (p>0.05) was observed between testicular SOD activities of the diabetic control 
(group 4) and diabetic rats treated with vindoline (group 5), (0.8313 ± 0.3629 ʮmol/mg 
versus 0.8900 ± 0.01505 ʮmol/mg), p>0.05. The difference between average testicular SOD 
activities of the diabetic control (group 4) and diabetic rats treated with glibenclamide (group 
6) was not significant (0.8313 ± 0.3629 ʮmol/mg versus 0.9517 ± 0.0446 ʮmol/mg), p>0.05.  
There was no significant difference between testicular SOD activities of groups 5 and 6 
(0.8900 ± 0.01505 ʮmol/mg versus 0.9517 ± 0.0446 ʮmol/mg), (p>0.05). Testicular SOD 
activities of all non-diabetic groups (Groups 1, 2 and 3) were significantly higher (p<0.05), in 
comparison to testicular SOD activities of the diabetic control (group 4); (1.063 ± 0.007962 
ʮmol/mg versus 0.8313 ± 0.3629 ʮmol/mg), (1.041 ± 0.03497 ʮmol/mg versus 0.8313 ± 
0.3629 ʮmol/mg) and (0.9725 ± 0.0347 ʮmol/mg versus 0.8313 ± 0.3629 ʮmol/mg) 
respectively. SOD activity in testicular tissues of diabetic groups 5 and 6 were not 
significantly different from testicular SOD levels of the normal control (group 1),  
 
Figure 4.9 compares epididymal SOD activities in diabetic and non-diabetic male Wistar rats 
after 5 weeks of subjection to various treatments. The difference in epididymal SOD activity 
between the normal control (group 1) and non-diabetic rats supplemented with vindoline 
(group 2) was not significant (2.117 ± 0.1476 ʮmol/mg versus 2.286 ± 0.2281 ʮmol/mg), 
p>0.05. Epididymal SOD activities of non-diabetic rats treated with glibenclamide (group 3) 
were not statistically different from epididymal SOD activities of the normal control (group 1), 
(1.841 ± 0.1348 ʮmol/mg versus 2.117 ± 0.1476 ʮmol/mg), p>0.05. No significant difference 
 62
was observed between epididymal SOD activities of groups 2 and 3 (2.286 ± 0.2281 
ʮmol/mg versus 1.841 ± 0.1348 ʮmol/mg), p>0.05. Epididymal SOD activities of the diabetic 
control (group 4), were significantly lower (p<0.05) in comparison to those of the normal 
control (group 1), (0.9938 ± 0.06395 ʮmol/mg versus 2.117 ± 0.1476 ʮmol/mg). The 
difference in epididymal SOD activities between the diabetic control (group 4) and diabetic 
rats treated with glibenclamide (group 6) was insignificant (0.9938 ± 0.06395 ʮmol/mg 
versus 1.104 ± 0.06542 ʮmol/mg), p>0.05. However, epididymal SOD activities of group 5 
subjects were significantly higher in comparison to those of the diabetic control (group 4), 
(1.513 ± 0.089 µmol/mg versus 0.9938 ± 0.06395 µmol/mg), p<0.05. 
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide  
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Figure 4.8: Testicular SOD activity of various groups after subjection to various treatments. 
Data is presented as mean ± SEM. (d) indicates significant difference of groups when compared to 
group 4 at p<0.05 and (e) indicates significant difference of groups when compared to group 5 at 
p<0.05. µmol/mg: micromoles per milligram. 
 63
Experimental GroupsE
pi
di
dy
m
al
 S
O
D
 A
ct
iv
ity
 ( 
m
ol
/m
g)
1 2 3 4 5 6
0
1
2
3
def
def
df
e
 
Figure 4.9: Epididymal SOD activity of various groups after subjection to various treatments. 
Data is presented as mean ± SEM. (d) indicates significant difference of groups when compared to 
group 4 at p<0.05; (e) indicates significant difference of groups when compared to group 5 at p<0.05 
and (f) indicates significant difference of groups when compared to group 6 at p<0.05. µmol/mg: 
micromoles per milligram. 
 
4.7. Effects of vindoline on testicular and epididymal catalase activity  
According to Figure 4.10, non-diabetic rats treated with vindoline (group 2) had higher 
testicular catalase activity in comparison to that of the normal control (group 1), (38.69 ± 
0.9186 ʮmol/mg versus 30.69 ± 0.9186 ʮmol/mg), p<0.05. The difference between testicular 
catalase activities of non-diabetic rats treated with glibenclamide (group 3) and the normal 
control (group 1) was not significant (24.77 ± 1.588 ʮmol/mg versus 30.69 ± 0.9186 
ʮmol/mg), p>0.05. The diabetic control (group 4) had significantly lower testicular catalase 
activity in comparison to that of the normal control (group 1), (23.65 ± 0.994 ʮmol/mg versus 
30.69 ± 0.9186 ʮmol/mg), p<0.05. Testicular catalase activity of diabetic rats treated with 
glibenclamide (group 6) were not statistically different from testicular catalase activity of the 
diabetic control (group 4), (19.08 ± 1.486 ʮmol/mg versus 23.65 ± 0.994 ʮmol/mg), p>0.05. 
Testicular catalase activities of group 5 were significantly higher in comparison to those of 
the diabetic control, (32.34 ± 1.589 ʮmol/mg versus 23.65 ± 0.994 ʮmol/mg). Furthermore, 
testicular catalase activities of group 5 were significantly higher in comparison of those of 
group 6 (32.34 ± 1.589 ʮmol/mg versus 19.08 ± 1.486 ʮmol/mg), p>0.05. 
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According to Figure 4.11, the difference between epididymal catalase activity of the normal 
control (group 1) and non-diabetic rats supplemented with vindoline (group 2); (62.66 ± 
0.5878 ʮmol/mg versus 63.54 versus 1.462 ʮmol/mg) and the difference between 
epididymal catalase activities of the normal control (group 1) and non-diabetic rats treated 
with glibenclamide (group 3); (62.66 ± 0.5878 ʮmol/mg versus 61.65 versus 2.396 ʮmol/mg), 
were not significant, p>0.05. The difference in epididymal catalase activities between groups 
2 and 3 was also insignificant (63.54 ± 1.462 ʮmol/mg versus 61.65 ± 2.396 ʮmol/mg), 
p>0.05. Epididymal catalase activity of the diabetic control (group 4) was significantly lower in 
comparison to that of the normal control (group 1), (27.73 ± 1.131 ʮmol/mg versus 62.66 ± 
0.5878 ʮmol/mg), p<0.05. Epididymal catalase activities of diabetic rats treated with 
vindoline (group 5) and diabetic rats treated with glibenclamide (group 6), were significantly 
higher in comparison to that of the diabetic control (group 4); (39.79 ± 1.587 ʮmol/mg versus 
27.73 ± 1.131 ʮmol/mg) and (38.60 ± 0.9332 µmol/mg versus 27.73 ± 1.131 µmol/mg) 
respectively, p<0.05. The difference in epididymal catalase activity between groups 5 and 6 
was statistically insignificant (39.79 ± 1.587 ʮmol/mg versus 38.6 ± 0.9332 ʮmol/mg), 
p>0.05. Overall, epididymal catalase activities of diabetic groups (4, 5 and 6) were 
significantly lower, (p<0.05), in comparison to those of the non-diabetic groups (1, 2 and 3).  
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide 
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Figure 4.10: Testicular catalase activity of various groups after subjection to various 
treatments. Data is presented as mean ± SEM. (b) indicates significant difference of groups when 
compared to group 2 at p<0.05, (c) indicates significant difference of groups when compared to group 
3 at p<0.05; (d) indicates significant difference of groups when compared to group 4 at p<0.05; (e) 
indicates significant difference of groups when compared to group 5 at p<0.05 and (f) indicates 
significant difference of groups when compared to group 6 at p<0.05. µmol/mg: micromoles per 
milligram.  
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Figure 4.11: Epididymal catalase activity of various groups after subjection to various 
treatments. Data is presented as mean ± SEM. (b) indicates significant difference of groups when 
compared to group 2 at p<0.05, (d) indicates significant difference of groups when compared to group 
4 at p<0.05; (e) indicates significant difference of groups when compared to group 5 at p<0.05 and (f) 
indicates significant difference of groups when compared to group 6 at p<0.05. µmol/mg: micromoles 
per milligram. 
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4.8. Effects of vindoline on testicular and epididymal FRAP levels  
Figure 4.12 illustrates testicular FRAP levels of diabetic and non-diabetic rats after being 
subjected to various treatments. The difference in testicular FRAP levels between the normal 
control (group 1) and non-diabetic rats treated with vindoline (group 2) was statistically 
insignificant, (3.285 ± 0.1319 ʮmol/g versus 2.374 ± 0.2127 ʮmol/g), p>0.05. There was no 
significant difference between testicular FRAP concentrations of the normal control (group 1) 
and non-diabetic rats treated with glibenclamide (group 3); (3.285 ± 0.1319 ʮmol/g versus 
3.483 ± 0.2617 ʮmol/g). The difference between testicular FRAP levels of non-diabetic rats 
treated with vindoline (group 2) and testicular FRAP levels of non-diabetic rats treated with 
glibenclamide (group 3) was not significant, (2.374 ± 0.2127 ʮmol/g versus 3.483 ± 0.2617 
ʮmol/g), p>0.05. The difference in testicular FRAP concentration between the diabetic 
control (group 4) and the normal control (group 1) was not significant (2.566 ± 0.1273 ʮmol/g 
versus 3.285 ± 0.1319 ʮmol/g), p<0.05. FRAP concentration in testicular tissues of diabetic 
rats treated with vindoline (group 5) were significantly higher in comparison to those of the 
diabetic control (group 4); (4.524 ± 0.4045 ʮmol/g versus 2.566 ± 0.1273 ʮmol/g), p<0.05. 
The mean testicular FRAP concentration of group 6 subjects was significantly higher in 
comparison to that of the diabetic control (3.941 ± 0.3147 ʮmol/g vesus 2.566 ± 0.11273 
ʮmol/g), p<0.05. The average testicular FRAP concentrations of group 5 and group 6 were 
not statistically different, (4.524 ± 0.4045 ʮmol/g versus 3.941 ± 0.3147 ʮmol/g), (p>0.05). 
 
Figure 4.13 compares epididymal FRAP levels between diabetic and non-diabetic rats 
subjected to various treatments for 5 weeks. The differences in epididymal FRAP levels 
between the normal control (group 1) and non-diabetic rats supplemented with vindoline 
(group 2), (3.007 ± 0.05471 ʮmol/g versus 2.402 ± 0.2198 ʮmol/g) and the difference in 
epididymal FRAP concentration between the normal control (group 1) and non-diabetic rats 
fed on glibenclamide (group 3), (3.007 ± 0.05471 ʮmol/g versus 3.371 ± 0.2077 ʮmol/g) 
were not statistically significant p>0.05. Epididymal FRAP levels of group 2 were however 
lower than those of group 3 (2.402 ± 0.2198 ʮmol/g versus 3.371 ± 0.2077 ʮmol/g). The 
difference between epididymal FRAP levels of the diabetic control (group 4) and normal 
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control (group 1) was statistically insignificant, (2.708 ± 0.04741 ʮmol/g versus 3.007 ± 
0.05471 ʮmol/g), p>0.05. Diabetic rats treated with vindoline (group 5) and diabetic rats 
treated with glibenclamide (group 6) had significantly higher epididymal FRAP activities 
p<0.05, in comparison to the diabetic control (group 4); (2.708 ± 0.04741 ʮmol/g versus 
3.702 ± 0.2126 ʮmol/g) and (2.708 ± 0.04741 ʮmol/g versus 4.372 ± 0.1498 ʮmol/g), 
respectively. The difference between epididymal FRAP concentrations of groups 5 and 6 was 
not significant (3.702 ± 0.2126 ʮmol/g versus 4.372 ± 0.1498 ʮmol/g), p>0.05. 
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide 
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Figure 4.12: Testicular FRAP concentrations of various groups after subjection to various 
treatments. Data is presented as mean ± SEM. (e) indicates significant difference of groups when 
compared to group 5 at p<0.05 and (f) indicates significant difference of groups when compared to 
group 6 at p<0.05. µmol/g represents micromoles per gram. 
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Figure 4.13: Epididymal FRAP concentrations of various groups after subjection to various 
treatments. Data is presented as mean ± SEM. (c) indicates significant difference of groups when 
compared to group 3 at p<0.05; (e) indicates significant difference of groups when compared to group 
5 at p<0.05 and (f) indicates significant difference of groups when compared to group 6 at p<0.05. 
µmol/g represents micromoles per gram 
 
4.9. Effect of vindoline on testicular and epididymal ORAC levels of Wistar rats 
Figure 4.14 illustrates the differences in testicular ORAC levels between diabetes-induced 
and non-diabetic Wistar rats after subjection to various treatments for 5 weeks. Testicular 
ORAC levels of non-diabetic rats treated with vindoline (group 2) were significantly higher 
(p<0.05), in comparison to those of the normal control (group 1), (5.109 ± 0.1298 ʮmol TE/g 
versus 3.710 ± 0.4902 ʮmol TE/g). The difference between testicular ORAC levels of non-
diabetic rats treated with glibenclamide (group 3) and the normal control (group 1), (3.892 ± 
0.3946 ʮmol TE/g versus 3.710 ± 0.4902 ʮmol TE/g) was non-significant, p>0.05. Testicular 
ORAC levels of group 2 were significantly higher than those of group 3, (5.109 ± 0.1298 
ʮmol TE/g versus 3.892 ± 0.3946 ʮmol TE/g), p<0.05. Treatment of diabetic rats with 
vindoline (group 5) resulted in significantly higher testicular ORAC levels in comparison to 
the diabetic control (group 4), (3.143 ± 0.08254 ʮmol TE/g versus 1.926 ± 0.1577 ʮmol 
TE/g), p<0.05. The mean testicular ORAC value for group 6 was however not statistically 
different from that of the diabetic control (group 4), (3.009 ± 0.1354 ʮmol TE/g versus 1.926 
± 0.1577 ʮmol TE/g) p>0.05. The difference between mean testicular ORAC values of 
 69
groups 5 and 6 (3.143 ± 0.08254 ʮmol TE/g versus 3.009 ± 0.1354 ʮmol TE/g) was also 
non-significant, p>0.05). 
 
Figure 4.15 illustrates epididymal ORAC levels of diabetic and non-diabetic Wistar rats after 
being subjected to various treatments for 5 weeks. Using the Bonferroni’s Multiple 
Comparison Test that compares all pairs of columns, epididymal ORAC levels of all non-
diabetic groups (1, 2 and 3) were significantly higher in comparison to those of all diabetic 
groups (4, 5 and 6).  Epididymal ORAC levels of non-diabetic rats treated with vindoline 
(group 2) were not statistically different from epididymal ORAC levels of the normal control 
(group 1); (7.209 ± 0.1479 ʮmol TE/g versus 6.663 ± 0.2992 ʮmol TE/g), p˃0.05. The 
difference between epididymal ORAC levels of the normal control (group 1) and non-diabetic 
rats treated with glibenclamide (group 3), was not significant (6.663 ± 0.2992 ʮmol TE/g 
versus 7.109 ± 0.1370 ʮmol TE/g), p>0.05. There was no significant difference between 
epididymal ORAC levels of groups 2 and 3 (7.209 ± 0.1479 ʮmol TE/g versus 7.109 ± 
0.1370 ʮmol TE/g), p˃0.05. The difference in epididymal ORAC levels between the diabetic 
control (group 4) and diabetic rats treated with vindoline (group 5); (3.809 ± 0.4244 ʮmol 
TE/g versus 4.571 ± 0.2455 ʮmol TE/g), the difference between epididymal ORAC levels of 
groups 4 and 6 (3.809 ± 0.4244 ʮmol TE/g versus 3.896 ± 0.2300 ʮmol TE/g) and the 
difference between epididymal ORAC levels of group 5 and group 6; (4.571 ± 0.2455 ʮmol 
TE/g versus 3.896 ± 0.2300 ʮmol TE/g) were statistically insignificant (p>0.05).  
 
Experimental Groups 
Group 1: Untreated, non-diabetic rats (normal control) 
Group 2: Non-diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 3: Non-diabetic rats treated with 50 mg/kg b.w. glibenclamide  
Group 4:  Untreated, diabetic rats (diabetic control) 
Group 5: Diabetic rats treated with 20 mg/kg b.w. vindoline  
Group 6: Diabetic rats treated with 50 mg/kg b.w. glibenclamide 
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Figure 4.14: Testicular ORAC levels of various groups after subjection to various treatments. 
Data is presented as mean ± SEM. (b) indicates significant difference of groups when compared to 
group 2 at p<0.05; (d) indicates significant difference of groups when compared to group 4 at p<0.05; 
(e) indicates significant difference of groups when compared to group 5 at p<0.05 and (f) indicates 
significant difference of groups when compared to group 6 at p<0.05.  
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Figure 4.15: Epididymal ORAC levels of various groups after subjection to various treatments. 
Data is presented as mean ± SEM. (d) indicates significant difference of groups when compared to 
group 4 at p<0.05; (e) indicates significant difference of groups when compared to group 5 at p<0.05 
and (f) indicates significant difference of groups when compared to group 6 at p<0.05. 
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CHAPTER FIVE 
DISCUSSION 
 
Previous research support the fact that diabetes mellitus contributes significantly to the 
generation of ROS and oxidative stress that leads to impairment of male reproductive 
function particularly in testicular and epididymal tissues (Ding et al., 2015). Medicinal plants 
are viewed as an easily available, potent source of antioxidants capable of scavenging free 
radicals and fighting diabetes-induced oxidative stress and have proven to be clinically 
effective and relatively less toxic than existing antidiabetic orthodox drugs (Sen et al., 2010; 
Bhatt et al., 2013). The World Health Organisation has therefore encouraged frontiers of 
scientific evaluation of diverse plant species for possible antidiabetic efficacy (Chikezie et al., 
2015).  
 
The present study sought to add scientific knowledge pertaining to the possible antidiabetic 
and antioxidant activities of vindoline (a bioactive ingredient from C. roseus), particularly in 
testicular and epididymal tissues. It follows scientific studies by Tiong et al, (2013) and Yao 
et al. (2013) who reported on the antidiabetic and antioxidant properties of vindoline. Tiong et 
al, (2013) reported that vindoline could enhance glucose uptake in β-TC6 and C2C12 cells in 
a dose-dependent manner and alleviate H202-induced oxidative stress in β-TC6 cells thereby 
showing its potential as an effective antioxidant. Additionally, Yao et al, (2013) reported that 
vindoline was able to enhance glucose-stimulated insulin release in a glucose- and dose- 
dependent manner by inhibiting Kv2.1 potassium channels and reducing the voltage-
dependent outward potassium currents. They reported that 20mg/kg b.w treatment with 
vindoline improved glucose homeostasis as reflected by its ability to increase the 
concentration of plasma insulin, protect pancreatic β-cells, decrease glycated haemoglobin 
levels, reduce blood glucose levels, reduce plasma triglyceride concentration and improve 
oral glucose tolerance test results. The present study investigated the antidiabetic potential 
of vindoline, its potential to reduce diabetes-induced oxidative stress and improve antioxidant 
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capacity in testicular and epididymal tissues using diabetes-induced adult Wistar rats as an 
experimental model. 
 
5.1. Induction of diabetes before various treatments. 
An ideal animal model of T2DM is expected to resemble as much as possible diabetic 
conditions seen in humans affected with T2DM. The administration of high energy diet and a 
single low dose STZ have been demonstrated to induce insulin resistance in animal models 
and partially destroy pancreatic β-cells leading to insufficient insulin secretion and closely 
mimicking the symptoms observed in human T2DM patients (Wilson & Islam, 2012).  
 
With regards to the present study, the possible therapeutic effect of vindoline against 
diabetes-induced oxidative stress in testicular and epididymal tissues was investigated using 
10% fructose water and STZ- induced diabetic male Wistar rats as an animal model. 
Diabetes was induced in male Wistar rats to be used as group 4, 5 and 6 subjects by feeding 
them on 10% fructose water for 2 weeks and thereafter administering a single intraperitoneal 
injection of STZ (40mg/kg b.w). Hyperglycaemia was observed 72 hours after STZ 
administration and this was confirmed by high fasting blood glucose levels in diabetes-
induced rats of groups 4, 5 and 6. As such, a T2DM experimental model was successfully 
created in rats to be used as groups 4, 5 and 6 subjects. These diabetes-induced rats were 
then subjected to various treatments with the aim of evaluating the possible therapeutic 
effects of vindoline against diabetes-induced oxidative stress effects in testicular and 
epididymal tissues. 
 
5.2. Evaluation of final body weights, testicular and epididymal weights after 
treatments 
 
This research project compared final body weights, epididymal weights and testicular weights 
of diabetic and non-diabetic rats subjected to various treatments for 5 weeks. Final body 
weights, epididymal weights and testicular weights of the diabetic control (group 4) were 
significantly lower in comparison to those of the normal control (group 1). These findings are 
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in agreement with results from previous studies by Abbasi et al, (2013) and Korejo et al, 
(2016) who reported reduced body weights, testicular weights and epididymal weights in 
diabetic animal models in comparison to their normal controls.  Insufficient insulin secretion 
and dysfunction in the insulin signalling pathways as seen in diabetic conditions result in 
disturbed glucose homeostasis. This prompts the body to use alternative sources of energy 
such as lipids and proteins instead of glucose by gluconeogenesis (Gannon & Nuttall, 2006). 
Diabetes is therefore usually associated with increased protein degradation, decreased 
protein synthesis and increased gluconeogenesis (Perry et al., 2016), that ultimately leads to 
rapid organ and body weight loss. Final body weights of non-diabetic treated groups (group 2 
and group 3) were also higher than those of the diabetic control (group 4) mainly due to 
undisturbed glucose metabolism and no muscle atrophy in these non-diabetic groups. As 
such, rats from non-diabetic groups (1, 2 and 3) were able to maintain high body weights in 
comparison to the diabetic control (group 4).  
 
Non-diabetic rats treated with vindoline (group 2) had significantly higher body weights in 
comparison to the normal control (group 1) showing the possible enhancing and protective 
effects of vindoline in terms of promoting increase in body weights in non-diabetic conditions.  
However, treatment of non-diabetic rats with vindoline (group 2) or glibenclamide (group 3) 
for 5 weeks did not have a significant impact on both testicular and epididymal weights in 
comparison to the normal control (group 1).  
 
Results of this study demonstrated that treatment of diabetic male Wistar rats with 20mg/kg 
b.w vindoline (group 5) or 50mg/kg b.w glibenclamide (group 6)  for 5 weeks did not have a 
significant impact in terms of increasing final body weights and testicular weights of diabetes-
induced, male Wistar rats when compared against the diabetic control (group 4). Vindoline 
and glibenclamide might have not been effective in reducing gluconeogenesis as seen in 
diabetic conditions. Diabetes is associated with increased gluconeogenesis which might 
precipitate organ and body weight loss (Gannon & Nuttall, 2006; Perry et al., 2016).  
Alternatively, failure of vindoline and glibenclamide to significantly improve body weight gain 
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and testicular weights in T2DM-induced rats of this study might have been due to a short 
treatment period or an insufficient dosage.  
 
Treatment of diabetic rats with 20mg/kg b.w. vindoline for 5 weeks slightly increased 
epididymal weights in comparison to the diabetic control (group 4) although the increase was 
not statistically significant (p>0.05). The average epididymal weight of diabetic rats treated 
with vindoline was however not significantly different from the mean epididymal weight of the 
normal control. It can therefore be concluded that the administration of vindoline was able to 
normalise epididymal weights in type 2-diabetic rats treated with vindoline for 5 weeks. 
 
5.3. The effect of vindoline on blood glucose and LPO levels in various treated groups. 
There is a close relationship between chronic hyperglycaemia, oxidative stress and LPO in 
the progression of diabetes mellitus (Maritim et al., 2003), and diabetes-induced sexual 
dysfunction is considered one of the most prevalent diabetic complications where oxidative 
stress plays an important role in its pathogenesis. Results of this study demonstrated high 
blood glucose levels and high oxidative stress as reflected by MDA levels in both testicular 
and epididymal tissues of the diabetic control. Final blood glucose levels of diabetic rats 
treated with vindoline remained significantly higher than those of the normal control. The 
inability of vindoline to restore blood glucose levels in these diabetic rats might have been 
due to a shorter feeding period, an insufficient dosage or simply the fact that vindoline is 
incapable of restoring fasting blood glucose levels in T2DM conditions to normal. In contrast, 
non-diabetic rats had normal fasting blood glucose levels after 5 weeks of treatment with 
vindoline and glibenclamide, mainly due to absence of diabetic pathology. 
 
Testicular MDA levels of the diabetic control were significantly higher in comparison to those 
of normal control. This finding is in-line with previous studies by Nelli et al, (2013) and 
Ostovan et al, (2016) who reported high testicular lipid peroxidation in diabetic rats. 
Treatment of diabetic rats with vindoline (group 5), was however able to reduce testicular 
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MDA levels to normal. These results therefore show that vindoline has the potential to 
restore normal oxidative balance in diabetic testicular tissues. 
 
Epididymal MDA levels of the diabetic control were also significantly higher in comparison to 
those of the normal control. This finding is also in line with previous studies by Nelli et al, 
(2013) and Ostovan et al, (2016) who reported high epididymal lipid peroxidation levels in 
epididymal tissues of diabetic rats. Although there was a significant reduction in epididymal 
MDA in diabetic rats treated with vindoline (group 5) when compared against the diabetic 
control (group 4), vindoline could not restore diabetic epididymal MDA to levels equal to 
those of the normal control (group 1). As such, it can be concluded that treatment with 
vindoline for 5 weeks can significantly reduce oxidative stress levels in epididymal tissues of 
T2DM- induced rats but not necessarily restore them to normal. Treatment of non-diabetic 
rats with vindoline (group 2) did not produce a significant difference in epididymal MDA levels 
when compared to the normal control (group 1). 
 
5.4. Evaluation of the effect of vindoline on testicular and epididymal SOD activity. 
Oxidative stress and LPO depletes antioxidant defence systems in diabetic conditions and a 
dysfunctional antioxidant system cannot protect tissues against ROS. As such, free radicals 
continue to accumulate leading to enhanced oxidative stress (Maiti et al., 2017). SOD is an 
endogenous antioxidant enzyme that detoxifies the superoxide anion into the less reactive 
H2O2 molecules via dismutation (Sheng et al., 2014). H2O2 is further detoxified by activities of 
glutathione peroxidase or catalase. Catalase is a haem-containing antioxidant enzyme that 
catalyses the detoxification of H2O2 into water and non-ROS (Birben et al., 2012). SOD 
therefore acts as the primary defence against superoxide radicals by preventing further free 
radical generation. Decreased activities of the SOD and catalase antioxidant enzymes in 
various tissues of diabetic rats clearly demonstrate that these antioxidant enzymes are easily 
inactivated by diabetes-induced ROS and lipid peroxides (Maritim et al., 2003).  
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No significant difference was observed in both testicular and epididymal SOD activity after 5 
weeks of treating non-diabetic rats with vindoline. The relatively normal levels of blood 
glucose, low MDA levels and normal catalase and SOD activity in both testicular and 
epididymal tissues of non-diabetic rats treated with vindoline (group 2) may be due to the 
absence of diabetic pathology in these rats. Non-diabetic rats used as group 2 subjects were 
not pre-exposed to 10% fructose water or STZ. As such, glucose levels in these rats 
remained normal, minimum levels of free radicals were produced and there was less 
oxidative stress in testicular and epididymal tissues of these rats. As a result of low oxidative 
stress, antioxidant enzyme activity was not altered and high SOD activity was maintained.  
 
Testicular SOD activity in the diabetic control (group 4) was significantly lower in comparison 
to that of the normal control (group 1). This finding is in line with previous studies by Xu et al, 
(2014), Afifi et al, (2015) and Fatani et al. (2015) who reported significantly low testicular 
SOD activities in diabetes-induced rats. Chronic hyperglycaemia in diabetic conditions 
promotes free radical production precipitating oxidative stress that is capable of altering 
antioxidant enzymes in various ways such that antioxidant enzymes’ activities are reduced. 
This leads to the accumulation of free radicals without adequate detoxification thereby 
enhancing testicular and epididymal oxidative stress. High oxidative stress due to chronic 
hyperglycaemia in diabetic rats might have altered SOD antioxidant enzymes leading to 
reduced SOD activity in testicular tissues of the diabetic control. Although the difference 
between testicular SOD activity of diabetic rats treated with vindoline (group 5) and the 
diabetic control (group 4) was statistically insignificant, there was no significant difference 
between testicular SOD activity of group 5 and the normal control. This shows that treatment 
of diabetic rats with vindoline has the potential to normalise testicular SOD activity in diabetic 
conditions. 
 
Epididymal SOD activity in diabetic rats treated with vindoline (group 5) was significantly 
higher than that reported for the diabetic control (group 4). This shows the possible efficacy 
of vindoline in improving epididymal SOD activity in diabetic rats.  Chronic hyperglycaemia in 
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diabetic rats decreased epididymal SOD activity, however, administration of vindoline was 
able to improve and significantly increase epididymal SOD activity although to levels not as 
high as those recorded for the normal control (group 1).  
 
5.5: The effect of vindoline on testicular and epididymal catalase activity. 
Testicular and epididymal catalase activities of the diabetic control (group 4) were 
significantly lower in comparison to that of the normal control (group 1). These findings are in 
agreement with previous reports by Nelli et al, (2013), Afifi et al, (2015) and Fatani et al, 
(2015) who reported low testicular and epididymal catalase activities in diabetes-induced 
animal models. Diabetes mellitus is associated with high levels of ROS which subsequently 
attack amino acids that are the building blocks of antioxidant enzymes leading to the 
modification and alteration of antioxidant enzyme activity. As such, diabetes is usually 
associated with low antioxidant activities (Maritim et al., 2003). 
 
Testicular catalase activity in non-diabetic rats treated with vindoline (group 2) was 
significantly higher in comparison to that of the normal control (group 1). This shows the 
potential efficacy of vindoline in enhancing testicular catalase activity in non-diabetic 
subjects. Additionally, treatment of diabetic rats with vindoline (group 5) increased testicular 
catalase activity to levels near normal. These findings show the potential of vindoline in 
restoring testicular catalase levels in diabetic conditions.  
 
Treatment of non-diabetic rats with vindoline (group 2) or glibenclamide (group 3) did not 
have a significant impact on epididymal catalase activity. However, treatment of diabetic rats 
with vindoline (group 5) and glibenclamide (group 6) significantly increased epididymal 
catalase levels in diabetes-induced rats although they could not restore epididymal catalase 
activity to normal. These results therefore show that vindoline can potentially improve 
epididymal catalase activity in diabetes-induced animal models but not necessarily restore it 
to normal.   
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5.6. Assessment of vindoline on testicular and epididymal total antioxidant capacity 
A number of assays are available to determine the total antioxidant capacity of biological and 
phytochemical compounds. The current study used the FRAP and ORAC assays to measure 
the effects of vindoline on testicular and epididymal total antioxidant capacity in type 2 
diabetic rats and non-diabetic rats.   
 
FRAP summarises the overall antioxidant power of a sample based on its ferrous ion 
reducing power by antioxidant vitamins and enzymes (Kiran et al., 2016). Results of this 
study showed no significant difference between testicular and epididymal FRAP levels of the 
diabetic control (group 4) in comparison to that of the normal control (group 1). Testicular and 
epididymal FRAP levels of diabetic rats treated with vindoline (group 5) and glibenclamide 
(group 6) were significantly higher in comparison to those of the diabetic control (group 4). 
Treatment of diabetic rats with vindoline (group 5) and glibenclamide (group 6) for 5 weeks 
increased levels of ferric ion reducing antioxidants possibly as a defence against diabetes-
induced oxidative stress in testicular and epididymal tissues of diabetes-induced Wistar rats. 
  
ORAC is an oxidation-inhibition based method that measures the ability of a specimen’s 
antioxidants to inhibit the oxidation of a fluorescent probe derived from peroxyl radicals by 
hydrogen atom transfer (Sahari & Berenji, 2015). The association between antioxidants and 
free radicals result in delayed fluorescent decay and high ORAC levels.  In diabetic 
conditions, the ROS-scavenging power of antioxidants becomes weakened resulting in 
diabetes-induced oxidative stress (Houcher et al., 2007).   
 
Testicular and epididymal tissues of the non-diabetic control (group 1) had higher ORAC 
values in comparison to the diabetic control (group 4). The absence of diabetic pathology in 
the normal control (group 1) was responsible for the high ORAC levels seen in this group. 
Poor glycaemic control in the diabetic control led to the accumulation of ROS and reduced 
antioxidant capacity as reflected by low ORAC levels.   
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Treatment of non-diabetic rats with vindoline (group 2) significantly increased testicular 
ORAC levels, showing the potential of vindoline to enhance testicular antioxidant capacity in 
normal subjects. However, treatment of non-diabetic rats with vindoline for 5 weeks did not 
have a significant impact on epididymal ORAC levels of group 2 as they remained high and 
within the normal range. Group 2 subjects had excellent glycaemic control, low levels of ROS 
and optimum antioxidant activity hence high testicular and epididymal ORAC levels.  
 
Treatment of diabetic rats with vindoline (group 5) significantly increased testicular ORAC 
levels to near-normal levels. This shows the potential of vindoline to restore testicular ORAC 
capacity in T2DM conditions. However, treatment of diabetic rats with vindoline did not 
significantly increase epididymal ORAC levels in type 2 diabetic rats. Group 5 epididymal 
ORAC levels remained significantly lower than that of the normal control after 5 weeks of 
treatment with vindoline, due to diabetic pathology.  
 
Overall, treatment of non-diabetic and diabetic rats with vindoline (group 2 and group 5 
respectively) significantly increased testicular ORAC levels in comparison to the normal 
control (group 1) and the diabetic control (group 4), respectively. This shows the potential of 
vindoline in enhancing testicular ORAC capacity in non-diabetic rats and its potential in 
improving testicular ORAC capacity in type 2 diabetic conditions. In contrast, administration 
of vindoline could not significantly improve epididymal ORAC levels in both non-diabetic rats 
and diabetic rats (group 2 and group 5 respectively). Results obtained in this study therefore 
show that treatment with vindoline for 5 weeks could not significantly enhance epididymal 
ORAC capacity in both non-diabetic (group 2) and T2DM conditions (group 5). 
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CHAPTER SIX 
CONCLUSION AND RECOMMENDATIONS 
 
Investigations performed in this study focused on using vindoline for supplementation and 
therapeutic treatments under normal and diabetes-induced oxidative stress conditions in 
testicular and epididymal tissues of normal and T2DM-induced male Wistar rats. This study 
investigated if treatment of adult male Wistar rats with 10% fructose water for 2 weeks and a 
single low dose intraperitoneal injection with STZ could induce sustainable chronic 
hyperglycaemia that closely mimics human T2DM. Furthermore, this study evaluated the 
possible efficacy of vindoline; an alkaloid extractable from C. roseus, in reducing fasting 
blood glucose levels, reducing testicular and epididymal oxidative stress and increasing 
antioxidant enzyme activity and total antioxidant capacity in T2DM-induced male Wistar rats. 
 
Diabetes-induced male Wistar rats demonstrated chronic hyperglycaemia, low body weights, 
low testicular and epididymal weights, high levels of testicular and epididymal oxidative 
stress and reduced oxygen radical absorption capacity in both testicular and epididymal 
tissues.  Short-term treatment of diabetic rats with vindoline for 5 weeks significantly reduced 
fasting blood glucose levels after 5 weeks of treatment. However, fasting blood glucose 
levels of the diabetic rats remained significantly higher in comparison to fasting blood 
glucose levels of normal subjects. There is therefore a need to investigate the 
antihyperglycaemic effects of vindoline on a long-term.  
 
Most results obtained in this study showed that treatment of diabetic rats with vindoline 
reduced lipid peroxidation levels, significantly increased antioxidant enzyme activities (as 
demonstrated by SOD and catalase activity assays) and increased the total antioxidant 
capacity as reflected by FRAP and ORAC assays in testicular and epididymal tissues. As 
such, findings of this study demonstrate the possible antihyperglycaemic effects as well as 
the antioxidant potential of vindoline treatment on testicular and epididymal tissues of 
diabetic and non-diabetic animal model.  
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Functional data such as spermatozoal motility and spermatozoal counts could not be 
performed due to lack of proper infrastructure. This limited our study to interpretation of 
oxidative stress biomarkers, antioxidant enzyme activities and total antioxidant capacity 
assays. There is therefore a need to investigate the possible efficacy of vindoline in 
ameliorating diabetes-induced oxidative stress in testicular and epididymal tissues using 
more advanced technologies.  Furthermore, there is a need to investigate the long-term 
effects of vindoline on testicular and epididymal function in T2DM conditions. Studies on the 
safety and dose-dependent effects of vindoline on male reproductive function in diabetic 
conditions are also necessary.  
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